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Cystic Fibrosis: an Historical Preamble 
 
 
 
 
“Das Kind sterbt bald wieder, dessen Stirne beim Kussen salzig schmeckt” 
“The child will die soon, whose forehead tastes salty when kissed”  
 
  German Children’s Songs and Games of Switzerland circa 1600
 
 
 
Current evidence suggests that more than 52,000 years ago a sudden human gene mutation 
took place in people living in Asia that resulted in a major change in the CF gene1. This event 
took place in the Palaeolithic period that corresponded to the post glacial warm epoch. It 
appears that at least three different mutations arose in humans living in the same geographical 
area. The circumstances under which these changes took place is unknown as are the actual 
people in which it arose but they were genetically distinct from any present European group. 
Subsequent emigration of people from the geographic regions of southern Russia, North 
Africa and the Middle East into Europe brought the gene mutations with them. Of particular 
importance was the transfer of the specific gene mutation we now refer to as ∆F508. It is 
hypothesised that the resultant admixture of these Indo-Europeans, Asians and North Africans 
led to biological and behavioural change. Among these changes was an alteration in diet. The 
consumption of grains and the introduction of cows’ milk into the diet required an ability to 
break down lactose. Interestingly, it has been suggested that the mutant CF alleles may have 
provided some advantage for the heterozygote carrier when these dietary changes occurred2. 
This advantage may have helped to secure the survival of these new settlers in Europe and 
their subsequent spread across the European continent.  
 
The descendants of these Neolithic people became strongly influenced by the supernatural. 
There was a belief that demons, magic powers and the evil eye were all intimately responsible 
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for the causation of the diseases to which they fell victim. Thus children who developed 
restlessness, vomiting or failure to thrive were considered bewitched (hexed) and this in turn 
led to the belief in later times that such children should not be baptised. The practise of 
licking the forehead of the children in a crosswise fashion was introduced. The idea behind 
this was to prevent or treat the bewitched state of the child. It is thought that this practise, in 
turn, had derived from the cleansing ceremonies that had been in vogue as a form of 
medicinal ritual to cure disease. When mothers perceived a salty taste on kissing or licking 
their child’s forehead, the children were then regarded as bewitched and therefore likely to die 
in the very near future. The relationship to CF is thus very interesting with it well established 
now those CF children have a very high sweat sodium and chloride content. Even to this day, 
some children are recognised early as having a ”salty taste” when kissed and this may lead to 
the seeking of medical advice and diagnosis prior to the onset of symptoms. 
 
The evidence of the superstition regarding the salty taste is drawn from numerous documents, 
the earliest dating from 16063.  Interestingly, these documents are derived from sources in 
twelve of the modern European states. Especially prominent are the German speaking 
countries of Germany, Austria and Switzerland, but reports also emanate from Spain, Russia 
and Italy. No source data is available from the British Isles or Sweden. The oldest of the 
above documents dating from 1606 was written by Juan Alonso y de los Ruyzes de Fontecha, 
Professor of Medicine in the University of Acala de Henares. The references are contained 
within his book “Diez previlegios para mugeres prenadas”4. 
 
It is well established that in CF, the pancreas of the patients can be macroscopically (naked-
eye) abnormal, being firmer, lobulated and having multiple cysts present.  In 1595 the 
Professor of Anatomy in Leiden, Pieter Pauw (1564-1617), dissected the body of an 11-year-
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old girl. The patient had been ill for eight years with failure to thrive and repeated fevers. At 
the post mortem examination she was found to have a swollen, scirrhous and enlarged 
pancreas which resulted in her death according to Pauw5.  Was this the first ever medical 
report of cystic fibrosis of the pancreas? Subsequently, Georg Seger (1629-1698), in 
Germany, treated a girl for three years who had failed to thrive, had diarrhoea, fever and 
vomiting. Following her death an autopsy revealed an enlarged indurated and scirrhous 
pancreas, which he attributed to the cause of her illness and subsequent death. Another 
important early report was that of Carl von Rokitansky (1838) from Vienna1. He described a 
child who died from perforation of the bowel and meconium peritonitis. This is the classical 
course of untreated meconium ileus that can be a neonatal presentation in 10-20% of infants 
with cystic fibrosis. It seems reasonable to accept this as very strong evidence of the existence 
of CF in earlier times. 
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Abstract  
 
 
“Her cabin’d ample Spirit, 
  it flutter’d and fail’d for breath 
 To-night it doth inherit 
 The vasty hall of death” 
 
The Scholar Gypsy 
Mathew Arnold 1822-1888 
 
 
 
Aim: 
 
The aim of this thesis is to describe the process by which the inherited disease, cystic fibrosis, 
(CF) was recognised as an important clinical entity in the United Arab Emirates (UAE) and 
the Sultanate of Oman (Oman). It examines the clinical presentation of the first patients and 
assesses their degree of severity. Further, it describes the first studies carried out to determine 
the underlying CF mutations associated with the disease in the UAE and Oman. An estimate 
is offered of the birth frequency of the condition. Overall, the cultural, geographical and 
historical aspect of the societies in which the disease occurs is stressed. 
 
Methods: 
An initial literature search was carried out using Medline of any literature pertaining to the 
Arab World and CF. This was read and classified into the relevance to Arabs in general, the 
Middle East and then specifically the Arab (Persian) Gulf societies. 
Thereafter, a clinic was established at Tawam Hospital, Al Ain, UAE, for children presenting 
with chronic respiratory disease that could serve as a national referral centre. It was run by the 
author as a service of the Paediatric Department of the UAE University Medical School. I sent 
a letter to every Paediatrician working in the UAE informing them of our clinic and offering 
our services for the diagnosis and management of chronic respiratory disease in children. This 
was based on the author's experience as a respiratory paediatrician in Australia and New 
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Zealand and as the Professor of Paediatrics in the UAE. No such service then existed in the 
UAE. 
Funding was sought to establish a research programme and develop a molecular genetics 
laboratory in the UAE Medical School. A series of successful research applications provided 
the grants to commence the investigations. Once a small number of children had been 
identified as having CF from those referred to the respiratory clinic, the initial project was to 
assess and report their clinical presentation. Following this an early start was made on the 
identification of the mutations responsible. Once these were established an attempt was made 
to estimate the frequency of the condition at birth. 
 
Additional clinical studies revolved around assessing the severity of the condition that was 
associated with the main mutations that were identified. A clinical comparison was made with 
those with the mutation ∆F508 and the other main mutation, despite the obvious limitation of 
small numbers then available. Radiological assessment was made to evaluate the progression 
of the disease. 
 
The final aspect of the study was to assess patients from Oman and compare their findings 
and mutations with the neighbouring UAE. Based on information gained hypotheses are 
proposed regarding the spread of the gene mutation by population drift. 
 
Thesis outline: 
A literature review is presented in the form of a critique on the disease and a résumé of the 
relevant aspects of the genetics of CF. Additionally, facts about the two countries' geography 
and history are presented. Finally, knowledge about CF mutations and population origins 
from other areas is presented. 
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The second main section deals with the clinical features of the disorder as it presents in the 
UAE. Molecular findings are then presented and details of the common mutation found in 
Bedouin Arabs. Hypotheses are then presented based on the information gathered. 
 
Results: 
CF is not a rare disease in the Arab children of the UAE and Oman. These findings refute 
previous reports of CF being a rare or non-existent disease in Arabs. The condition presents 
with a severe clinical picture, with early colonisation of the respiratory tract with 
staphylococcus, haemophilus and pseudomonas organisms, even with conventional CF 
management practices in place.  
 
The CF mutation S549R is prevalent in Arabs of Bedouin stock, while ∆F508 is found in 
those of Baluch origin. The former may be descendants of Arabs who left southern Arabia 
and travelled to the Trucial Coast at the time of the destruction of the great dam at Marib. The 
origins of this mutation may lie in the area that corresponds to the modern Republic of 
Yemen.  The latter groups are descendants of those who came originally from Baluchistan. It 
is hypothesised also that the ancestral home of the ∆F508 mutation may be in the 
geographical area now known as Baluchistan, that spans three separate modern political 
territories. The evidence presented supports the concept that the S549R mutation may be 
associated with a severe, if not the severest, clinical pattern recognised. It equates with that 
seen with the homozygous ∆F508 genotype. The absence of an additional mutation in the 
promoter region accounts for the different clinical pattern seen in previously described 
patients. 
 
Conclusions: 
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There needs to be a major awareness of the presence of CF as a severe clinical disease in the 
children of the Gulf States. The clinical presentation and findings support the concept of 
under recognition of the disease. Climatic conditions put the children at special risk of 
hyponatraemia and electrolyte imbalance. The absence of surviving adults with the disease 
suggests premature deaths have occurred, but the high fertility rates have maintained the gene 
pool for this recessive disorder. 
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Chapter 1 
 
Introduction 
 
 
 
 
“There are two things which I am confidant I can do well:  
   One is the introduction to any work, stating what it is to 
   Contain, and how it should be executed, in the most perfect manner” 
 
Life of Johnson vol. 1 p 292 (1755) 
Samuel Johnson (1709-1784) 
 
 
The Arab world, in general, and the Eastern Arabian Peninsula, in particular, is characterised 
by a rich history and culture and has a strong mixture of religious and traditional beliefs. 
While the Bedouin population of the region tends to be homogeneous, especially in the 
United Arab Emirates (UAE), the people of the Sultanate of Oman (Oman) tend to be more 
heterogeneous. They possess a rich admixture of genes from Bedouin Arabs, Persians, Turks, 
Asian sub-continentals, Africans and Europeans. Indeed, in one small area of the Musandam 
Peninsula, the local “Arabs” claim direct descent from the Portuguese who invaded the area in 
the 18th Century. In addition, the region has a “majority” population of “guest workers”, 
originating, in the main, from India and Pakistan, but has drawn people from every corner of 
the globe. Despite many of these people having lived in the Gulf countries for decades, they 
are not integrated into society and have no rights of ownership or permanent residence. 
Citizenship of the Gulf States is very rarely given to anyone born outside of the country and 
almost never to anyone who is not a Moslem. Thus the term “National” refers almost 
exclusively to Arabs who are Moslems born in the Arab states of Oman or the UAE. It is, 
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however, with the indigenous people of these two countries that our studies have been 
concerned with and directed at solely and not with the ex-patriate residents.  
 
It is frequently stated that the inherited disease, cystic fibrosis (CF) is rare in those of African 
and Asian descent. Similarly, there has been a belief that the disease is rare or non-existent in 
Arab populations1. Teebi has regarded this assumption as surprising as Arabs are of 
Caucasian descent in the main, and CF is regarded as the most common lethal genetic disease 
in Caucasian populations1. 
 
My interest in the existence of CF in Arab children was initiated and stimulated by my being 
asked to see an eight year old Emirati girl on the day I commenced duties as Professor of 
Paediatrics in the Tawam Hospital and the Medical School in Al Ain, UAE. The child was 
clearly moribund and had all the clinical stigmata of chronic lung disease and respiratory 
failure. She subsequently died of cor pulmonale. However, blood samples obtained prior to 
her death permitted laboratory studies and a molecular genetic analysis to later confirm that 
she had, indeed, died as a result of CF and some of its many complications and these had 
resulted in her premature death. Autopsy examinations are not carried out in the Arab States 
on the basis of religious belief, except where there may be a forensic indication. Thus a post-
mortem examination was not an option open to us to assess further the cause of death and its 
associated pathology. 
 
The question was then raised as to whether such events were commonplace or not in the 
Emirates. No record existed in this specific hospital of similar children, or more correctly, 
children given a similar diagnosis. Tawam Hospital acted as the unofficial tertiary referral 
hospital for children due to its University affiliation status. Review of the medical literature in 
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the UAE, revealed that there had been two case reports of children suspected clinically of 
having CF and who were later confirmed to have the condition by having elevated sweat 
chloride levels on testing by the pilocarpine iontophoresis method (sweat test)2, 3. The 
children involved were all UAE nationals. The first report in 1987 described an 
undernourished four-year-old with diarrhoea. Investigations revealed an elevated sweat 
chloride, but there was no evidence of chronic lung disease. The second report, in 1991, 
described two children, one with meconium ileus and the second with malabsorption 
characterised by bulky stools and failure to thrive and frequent chest wheezes. Several 
important points were raised in the reports. The authors noted there was consanguinity in the 
marriages, Baluch descent and origins in the Northern Emirates (Ras-al-Khaimah and 
Sharjah). In addition, the patient with meconium ileus may be, in retrospect, the only UAE 
National to have been observed to have had this neonatal complication of CF. 
 
This thesis is intended, therefore, to describe the process of establishing the fact that CF was 
an important disease in the Eastern Arabian Peninsula. It describes the Arab children affected, 
the molecular genetics of the condition and the severity of the clinical presentation. The 
approach I have taken is to report each step as it was achieved over a number of years. It does 
involve, therefore, some repetition and duplication within the text as consolidation of 
knowledge occurred and the increased patient pool was established. This method has the 
advantage of “real time” as the jigsaw was completed. To fit the pieces together, I have drawn 
directly from many of the original research papers and material. Again, the disadvantage of 
this is some repetition within the text, but it does demonstrate evolution of the research plan. 
To make it easier for the reader, I have placed the appropriate references at the end of each 
chapter. 
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The research plan was “dictated”, in part, by our need and ability to satisfy the research 
funding organisation and its grants committee that our intentions were logical, practical and 
were directed at the needs of the local population. Health Science research funding in the 
United Arab Emirates (UAE), at that time had a directive to be relevant to the needs of the 
national Arab population and have an immediate practical application to the UAE society. 
 
The establishment of a hospital based clinical service for CF, permitted the acquisition of 
information about the probable patients and permitted the subsequent practical application of 
any knowledge gained from the research. Thus, rapid diagnosis and management of the 
disease could take place. No such facility existed in the UAE at that time and any patients 
with chronic respiratory disease were sent overseas if the family could secure funding. 
 
This thesis thus covers the investigations that have led to the identification of CF in eastern 
part of Arabia. It provides information that is leading to the establishment of the molecular 
genetic basis of the disease in Arabs. While the UAE and Oman are two of the most rapidly 
developing countries in the world, the background of genetic disease in the area has not been 
investigated. It is strongly influenced by history and the cultural habit of consanguineous 
marriage. Despite its economic strength, the UAE has yet to achieve excellence in medical 
care, while Oman with lesser revenue is leading the region by its progressive and enlightened 
approach.  
 
I report herewith the unravelling of some of the background to CF in the region, which has 
been achieved over several years and despite the above remarks has been funded by the UAE 
government through the University system. 
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Chapter 2 
 
The Clinical Disease 
 
 
”For death and life, in ceaseless strife, 
 Beat wild on this world’s shore 
 And all our calm is in that balm 
 Not lost but gone before” 
 
Not Lost But Gone Before 
Caroline Norton (1808-1877) 
 
 
CF results in progressive lung disease, pancreatic dysfunction and elevated sweat electrolytes 
and in males, infertility.  There are wide variations, however, in the clinical expression and 
the mode of presentation of the disorder. These variations are dependent on the time at which 
clinical signs are manifest and this time can vary from birth to middle adult life.  
 
The purpose of this chapter is to explore what is relevant regarding the clinical presentation of 
CF to patients emanating from the Arabian Peninsula. It is not intended to reiterate the vast 
literature on CF and all the details of its clinical manifestation and presentation. There are 
numerous good reviews and texts that have performed this function1-3. These are invariably 
orientated from a Western viewpoint or more specifically to patients of European descent.  
 
Life expectancy of CF patients in the Western World has increased considerably in recent 
years and the current predicted median life expectancy in the United Kingdom is forty years4. 
This is attributed to the advent of the newer therapies and regular contact with CF centres5.  
There is evidence also, that early diagnosis and the introduction of newborn screening is an 
important additional factor6, 7. There is certainly no evidence available regarding an 
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improvement in the prognosis and better outcomes for children from non-Western countries. 
The only previous attempt in an Arab country to screen a population and to establish a 
frequency of the disease was in Jordan. Nazer used the method of the detection of albumin in  
meconium as his screening test. He did identify three children by this method but did 
acknowledge the severe limitations of the technique. Importantly he did stress that atypical 
presentations were likely in his population8. Until the last decade, there have been no attempts 
to define the severity of the disease in Arabia, its clinical presentation and prognosis.  
 
Wallis9 has observed that over the last 30 years suggestive clinical symptoms or a family 
history and a positive sweat test have been used for confirmation of the clinician’s suspicions 
of CF. The disease presentation was characterised by the clinical features of chronic 
obstructive pulmonary disease, pancreatic enzyme deficiency and small intestinal obstruction. 
The diagnosis was then confirmed by the classic sweat test10. It had been recognised, 
however, that there could be borderline sweat test results or negative sweat tests in the face of 
convincing clinical evidence. These concepts did cause confusion and the technique and 
quality of the sweat test performed on the individual patient was often questioned9.  
CF was known to be an autosomal recessive disorder. It was not until the discovery of the 
gene for the cystic fibrosis transmembrane conductance regulator (CFTR), however, that it 
was demonstrated that in Western Countries approximately 70% of CF clinical disease was 
due to the presence of the gene mutation referred to as ∆F508 (see later Chapter). Importantly, 
the presence of homozygosity for the mutation appeared to impart pancreatic insufficiency to 
the individual. However, there appeared to be little phenotype–genotype correlation with 
regard to the other clinical presentations of the disease.  
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Two events are of particular relevance to the clinical phenotype of CF in Arabs. First, was the 
recognition that while the ∆F508 mutation was the commonest mutation, there were other 
CFTR gene mutations? Subsequently, over 1,000 mutations and sequence changes have been 
described which can be associated with clinical disease11. Indeed, the prior conundrum of 
negative sweat tests in CF12 is explained by the presence of differing mutations at different 
sites on the gene. The concept of the spectrum of clinical disease being associated with 
different mutations is now increasingly accepted. However, phenotype-genotype correlation is 
highly complex and there is now recognition that there are many factors involved. Three main 
factors are recognised which contribute to variability in the CF phenotype. These include the 
specific pair of CFTR gene mutations, variations in the remainder of the genome and the 
possibility that other genes may compensate for the chloride ion channel dysfunction13. 
Finally, environmental and therapeutic intervention may be relevant. Reported later are our 
findings in relationship to rare mutations of the CF gene. Further, the finding that one newly 
described additional gene mutation can influence the clinical severity of another pair of 
mutations is presented later.  
 
Pancreatic insufficiency is present in about 90% of patients with CF.  It is associated with 
several mutations within three of the five classes of mutations (see later Chapter). Examples 
of these mutations include ∆F508, G542X and R334W. Congenital bilateral absence of the 
vas deferens (CBAVD) in CF compounds the confusion. This condition leads to infertility in 
about 99% of male patients and is almost universal in classical CF. In some individuals it can 
also be the presenting symptom of milder and rarer mutational variants. They may form the 
very mild end of the clinical spectrum of the disease. It appears that in the embryonic 
development of the vas deferens there is a requirement for a higher level of CFTR activity, 
greater than 10%14. Thus some of the "minor" mutations may reduce the CFTR activity to less 
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than this amount but may allow sufficient activity to result in pancreatic sufficiency (see 
Figure 11, Chapter 3). The sweat chloride levels, while helpful in diagnosis, appear to be 
unhelpful in terms of quantifying the severity of the disease and the higher levels do not 
necessarily equate with severe clinical disease15.  
 
The increasing knowledge of the molecular basis of CF has, in fact, confused the concept of a 
“clinical disease” rather than clarifying the issue. The dilemma is as to what actually 
constitutes clinical disease. Wallis9 has outlined this in a diagrammatic form  (Figure 8) and 
has asked the question as to “what constitutes a CF diagnosis?” One extreme is a healthy male 
with CBAVD and two CF mutations as compared to the girl with nasal polyps and a normal 
sweat test, recurrent chest infections and the detection of one CF mutation. Which has CF? 
Wallis9 stresses the consequences of such a diagnosis on educational opportunities, insurance 
status and the workplace. He cites the dilemma of homogeneity for the mutation 
3849+10kbC→T. It is associated with severe bronchiectasis, but with a normal sweat chloride 
level and male infertility.  
 
Kerem and Kerem16 have classified phenotypes into (a) severe (b) mild (c) extremely 
variable. The severe phenotype is characterised by early onset disease, high sweat chloride 
levels and pancreatic insufficiency. While ∆F508 mutations are associated with severe disease 
presentation, it is being recognised increasingly that other mutations are associated with 
severe disease. Kerem and Kerem16 have listed the characteristics of CF patients having mild 
and severe phenotypes (Table 1). They have gone further and classified mutations according 
to the severity of the phenotype (Table 2). The group described as having variable phenotypes 
poses difficulty. Pulmonary involvement varies considerably in those carrying the same 
mutations. Several mutations are associated with such variability. The G85E mutation is one 
 39
such example. Many of the clinical measures seem to vary in different individuals such as the 
time of onset, age at diagnosis, respiratory involvement, sweat electrolyte levels and 
pancreatic sufficiency or insufficiency. Similarly, the severity of lung disease varies 
considerably, but to add to the confusion, the disease manifestations differ between siblings. 
Some may develop liver disease while others do not. 
 
To provide a sense of balance, however, the possession of a positive sweat test and two CF 
mutations and clinical disease does provide evidence of CF. However, those with an unusual 
phenotype and borderline sweat electrolyte levels do require genotyping for the less common 
mutations. This should be followed by a thorough evaluation of the respiratory tract e.g. 
microbiology of the sputum, radiological imaging, evaluation of pancreatic function and 
urogenital assessment e.g. by ultrasound. Thus, “classical” disease is characterised by chronic 
obstructive pulmonary disease, pancreatic enzyme deficiency, small intestine obstruction and 
male infertility. Untreated disease results in death from pulmonary infection. 
 
The second important event in relation to CF in the Arab world was the steady recognition 
that delays in diagnosis of CF were occurring in children of ethnic minorities and those of 
mixed origins living in the UK17. It was being recognised further that the disease was present 
in those from cultures previously considered free of the disorder. Teebi and Farag18 in their 
monograph on the Genetic Disorders among Arab Populations quote the old belief that CF is 
rare or non-existent in Arabs. They comment that this view is surprising because of the 
Caucasian descent of many of them. Thus, there has been a steady increase in the 
documentation of CF patients of African, Japanese and Chinese descent19. Spencer17 reported 
patients of Indian, Pakistani and Bangladeshi origins. Studies from the United States have 
given an estimated incidence in Native Americans as 1:80,000, while in the Black population 
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the figure has been put at 1:17,00020. 
 
It became apparent that as new and different genotypes were becoming recognised that there 
was often a relationship between the phenotype and the geographical area as well as historical 
events. Examples of such occurrences are the association of the G551D mutation and its 
distribution in areas of Europe, which correspond to the past populations of Celtic descent. 
Similarly the R553X mutation reflects those of Germanic origin, while 1717,1G→A is found 
in Switzerland and Northern Italy21. 
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Figure 8 
 
Spectrum of Phenotype manifestations 
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Table 1 
Clinical characteristics of CF patients having 
mild and severe phenotypes 
 
 
 
 
 
 
 
    Severe 
phenotype 
       Milder 
phenotype 
 
 
Type of mutation Two severe mutations At least one mild 
 mutation 
Age of diagnosis Early (usually< 1 year) Late (usually > 10 years) 
Pancreatic function Pancreatic insufficient 
(>95%) 
Pancreatic sufficient 
 (70-80%) 
Nutritional status Poor Good 
Meconium ileus High incidence Not present 
Sweat chloride levels High (> 80mmol/L) Usually 40-80 mmol/L 
Pulmonary function Variable Variable 
Male fertility None Possible 
 
 
After Kerem E, Kerem B. Genotype – phenotype correlations in cystic fibrosis. Pediatric Pulmonology 1996; 22: 
387-395. 
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Table 2 
 
Classification of mutations according to 
phenotype severity 
 
 
Severe Milder Substantial 
variation 
 
 
1078delT R117H G85E 
∆F508 A455E R334W 
1717-1G→A 3849+10kbC→T 5T 
G542X R334W R347P 
G551D R347H  
R553X R352Q  
621+1G→A 2789+5G→A  
W1282X   
N1303K   
1811+1.6kbA→G   
1677delTA   
R347P   
 
After Kerem E,  Kerem B. Genotype-phenotype correlations in cystic fibrosis. 
Pediatric Pulmonology 1996; 22: 387-395 
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Chapter 3 
 
 
The “New Genetics” and Cystic Fibrosis 
 
“Pale despair and cold tranquillity 
  Nature’s vast frame, the web of human things, 
  Birth and the grave, that are not as they were.” 
 
Alastor 1, 718 
Percy Bysshe Shelley (1792-1822) 
 
 
The last twenty years have seen a spectacular change in our knowledge of and ability to 
manipulate deoxyribonucleic acid (DNA). The first recombinant DNA molecules were 
generated in 1972 and twenty years later; DNA diagnosis had become the mainstay in such 
conditions as CF and Duchenne muscular dystrophy. While there may be up to 50,000 human 
genes encoded in the DNA, we are concerned here with the gene relating to CF and its gene 
product.  
 
The rapid accumulation of this knowledge has been dependent upon the major progress made 
in techniques allowing the manipulation and study of DNA. An important early step was the 
improved methods of extraction of DNA from blood and tissue. The development of 
hybridization methods by which heat applied to double stranded DNA permitted comparison 
of DNA strands. The use of heat and cooling led to the development of polymerase chain 
reaction (PCR) techniques. The discovery that bacteria produced restriction enzymes that 
cleaved specific DNA sequences permitted the recognition of heritable restriction sites and 
the subdivision of long chains of DNA into manageable fragments. PCR technology allowed 
the amplification and copying of regions of the genome demarcated by primers1. 
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It was established in the early 1980s that the basic physiological defect in CF was a failure of 
regulation of chloride transport1. However, in 1989 the gene responsible was located on 
chromosome 7, region q21-22. The gene is approximately 250,000 base pairs in length, 
contains 27 exons and encodes a 1480 amino acid polypeptide, with a molecular weight of 
170,000 daltons. It has been named the cystic fibrosis transmembrane conductance regulator 
(CFTR)3,4,5. It consists of two repeated motifs, each consisting of a domain capable of 
spanning the membrane six times and a domain called a nucleotide binding fold, which binds 
and hydrolyses ATP. It has been classified as a member of the ATP binding-cassette super 
family. While the evolutionary basis and interaction of CFTR with other ion channels is not 
fully understood, the abnormal CFTR is related to a lack of chloride recapture leading to an 
osmotic effect. In the pancreas the effect is obstruction due to the clogging of its ducts by 
abnormally viscid secretions. Thus in these tissues CFTR normally mediates chloride 
secretions, not reabsorption6. Study of the aminoacid sequence of the CFTR has led to a 
prediction of the structure of CFTR. This is outlined in Figures 9 and 10. 
 
Gene expression is highly tissue specific. The CF gene is detectable in the epithelial lining of 
certain organs only. The majority of the sites are ductal – pancreatic ducts, sweat glands, male 
genital ducts and the proximal and distal kidney tubule. It is also found in the lung epithelium, 
jejunum and colon7. 
 
The promoter region of the gene, which is normally involved with transcription, is as yet not 
fully understood in the CF gene. In the flanking region 5´ to this area there is a lack of a 
TATA box, but it does include a GC-rich region. There are several putative regulating signals 
including two consensus GC boxes (GGGCGG) which may be sites of regulation of phorbol 
esters8. Reference to this promoter region will be made in a later chapter. 
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Figure 9 
 
Organisation of CFTR in relation to functional 
domains 
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Figure 10 
 
 
Predicted structure of the CFTR 
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The aspect of particular importance in relation to this dissertation was the discovery of the 
array of mutations that can occur in the CF gene. At molecular level these mutations include 
missense mutations, premature stop codons, small insertions and deletions causing 
frameshifts, in-frame deletions and mutations that effect splicing. However, no large deletions 
have been demonstrated and early reviews stated that no mutations occur in the promoter 
region7. Important evidence is included later to refute this statement and to demonstrate that 
promoter region mutations may be important in the development and manifestations of 
clinical disease.  
 
The Cystic Fibrosis Genetic Analysis Consortium has been pivotal in the international 
collaboration that has occurred in the documentation of novel mutations of the CF gene and 
the population genetics of the different mutations. At the time of writing over 1,000 mutations 
and sequence variations have been recorded9. It soon became apparent that the three base pair 
deletion called ∆F508 was the most common deletion. It is a result of a shortening of the 
CFTR by one aminoacid, phenyalanine (F), at position 508 on the protein. In a worldwide 
survey of 43,849 CF chromosomes it accounted for 66% of all CF mutations9.  
 
The CFTR gene (Figure 9) and the model of the protein (Figure 10) indicate that mutations 
occurring in certain exons are more likely to produce major biological effects. The first 
membrane-spanning domain (MSD1) is coded for by parts of exons 3, 4, 6a and 7. One well-
recognised example of a MSD1 change results from a mutation in exon 4, due to the 
621+1G→T mutation, which is relatively common. Mutations occurring in the nucleotide-
binding fold (NBF1, NBF2) representing exons 9-12 and 19-22 provide the largest cluster and 
are responsible for 70% of disease associated mutations of the CFTR in Western Countries7. 
The ∆F508 mutation is the common example of NBF1 mutations. Conversely, exon 13, which 
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codes for the regulatory domain (R), contains relatively few mutations compared to the rest of 
the CFTR. All are rare, however. 
 
Mutations in the second membrane-spanning domain (MSD2) are rare except for those in 
exon 17b, but these do not equate to the cluster in the equivalent position in the MSD1. 
Finally, the NBF2 (19-22) is also a site of disease associated mutations. Those localised to 
exons19 and 20 are particularly common. Of special note is a stop codon due to mutation 
W1282X. Similarly, N1303K on exon 21 is relevant to future clinical observation in this text. 
 
It would appear that disease-causing alterations that are compatible with survival are situated 
within the two nucleotide-binding folds of the protein. This observation does indicate the 
functional importance of these regions of the CFTR. Interestingly, the disease related 
mutations are thus spread in a non-random fashion. There are twice as many in NBF1 than in 
NBF2 and twice as many in the first part of the protein as to the second part.  
 
In the nomenclature of the mutations, those named by a position plus or minus a second 
number occur in introns and interfere with messenger RNA splicing (e.g. 3849+10kbC→T). 
Those ending in “X” create a premature stop codon (e.g. G542X). Those labelled “del” 
involve loss of a single nucleotide, causing a frameshift in the gene’s code (e.g. 2184delA). 
 
There has been recent progress in the understanding of how CF-associated mutations cause a 
loss of CFTR chloride channel function. The location of the mutations in the exons of the 
gene and the DNA and their relation to sites on the protein has already been outlined. In 
Chapter 2 the degree of disease severity was discussed in relation to recognised specific 
mutations. Here, the effects of the mutation are discussed in terms of cellular action. There 
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have been five mechanisms described by which the mutations cause a loss of function10,11. 
Table 3 shows the classes, the involved domain and the resultant effect upon pancreatic 
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Table 3 
 
 
Classes of CFTR Mutations that cause CF 
 
Class Defect Example Domain Clinical 
effect 
1 Protein 
production 
   
 Nonsense G542X NBD1 PI 
 Frameshift 3905 insT NBD2 PI 
 Splice 621+ G→T MSD1 PI 
II Processing ∆F508 NBD1 PI 
III Regulation G551D NBD1 PI 
IV Conduction R117H MSD1 PS 
V Synthesis 3849 + 10kb 
C→T 
Splice PI/PS 
     
Key: PI = Pancreatic insufficiency,  PS = Pancreatic sufficiency  
MSD = Membrane spanning domain, NBD = nucleotide-binding domain 
 
After: Welsh MJ, Smith AE. Cell 1993; 73: 1251-54., Estivill X. Nature Genetics 1996; 12: 
348-350. 
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function. It should be appreciated that any specific mutation may result in more than one type 
of dysfunction such as defective processing and defective regulation12. Class 1 mutations are 
found throughout the gene and result in premature termination signals because of splice site 
abnormalities, frame shift due to insertions or deletions or nonsense mutations. The mutation 
R553X results in unstable mRNA and no detectable protein. All class 1 mutations produce 
little or no full-length protein; thus they should cause a loss of CFTR chloride channel 
function in affected epithelia. 
 
In class II, the several mutations in this group fail to traffic the protein to the correct cellular 
location. These mutations include the most common mutation, ∆F508. The failure of the 
CFTR to mature to the fully glycosylated form results in it being degraded. Thus, the protein 
cannot be detected at the cell surface, or it is present in very reduced quantities in the apical 
membrane. The degradation process involves the CFTR being relocated (or mislocated). This 
process is considered to be due to the failure of the CFTR to fold correctly and thus it is 
prevented from taking its position in the membrane. Denning et al.12 showed that for 
CFTR∆F508 when incubated at 23-30ºC, some of the mutant protein escapes from the 
endoplasmic reticulum, is fully glycosylated in the Golgi complex and is delivered to the cell 
membrane. It appears to retain some function, the level of which may be one third of the wild 
- type of CFTR. 
 
Class III mutations are those which result in defective regulation. Intra-cellular ATP regulates 
the opening of CFTR chloride channels through direct interactions with nucleotide binding 
domains. Many of this type of mutation occur in the nucleotide binding domains and hence it 
is likely that they will result in alterations in channel function. There is a wide variation, from 
the minimum function associated with mutation G551D to the good function associated with 
 54
mutation G1244E. CFTR also regulates phosphorylation of the regulatory domain. Welsh and 
Smith10 speculate that this function may be redundant and mutations in this area are not likely 
to produce CF.  
 
Finally, mutations in the membrane-spanning domains are now thought to be involved with 
the channel pore. It appears that when the mutants are expressed, the membrane-spanning 
sequences are correctly processed and present in the apical membranes. The resultant 
regulation appears similar to that of the wild type but the current is reduced. There appears to 
be a gradation in effect with wild-type CFTR> R347P >R117H >R334W. The explanation of 
this finding may be in the time duration that the channel is open and hence the rate of ion 
flow10. The classes of mutation can be represented in a diagram to show the biosynthesis and 
function of CFTR in an epithelial cell (figure 11). 
 
Riordan13 has proposed that CF is a disease of the misprocessing of CFTR glycoprotein. The 
mutant CFTR protein fails to mature or to proceed beyond the endoplasmic reticulum within 
the cell. The ∆F508 variant results in local misfolding of the protein and the loss of its normal 
shape. This improper folding is detected within the cell and the protein produced is selected 
for degradation. The basis for this is a form of biosynthetic quality control. Failure of this type 
of control results in a disease process of its own in other biological situations. Examples of 
these are amyloid disease and α-1-antitrypsin deficiency where cellular function is disrupted 
by the accumulation of such aggregates. The fate of the mutant CFTR molecule is illustrated 
in figure 12. As stated before, there is experimental work indicating that temperature 
manipulation of cell culture systems promotes maturation of the protein and allows 
transportation of the variants to the cell surface. How the selection process for altered proteins 
occurs is unknown. However, wild-type and variant CFTR interacts with multiple molecular 
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chaperones on both sides of the endoplasmic reticulum (ER) membrane. The ∆F508 variant is 
potentially functional and treatments to provide the maturation of the misfolded protein could 
prove a useful tool in the management of CF13. Any method that could prevent the initial 
misfolding of the protein could perform this function and serve the purpose of channel 
survival. Certain in vitro manoeuvres including the use of glycerol can influence protein 
folding, but as yet none have an in vivo potential. Another approach may be to promote the 
action of chaperones and hence stimulate maturation of the CFTR that way13. 
 
The expanding knowledge of genes, their polymorphisms and mutations has given rise to the 
study of their geographic distribution. This distribution provides insight into population 
history and the evolution of inherited diseases. When this knowledge and technique is applied 
to CF, like many other aspects of the disease, we end up with more questions than answers. 
Barbujoni13 has summarised many of the questions we need to ask in assessing CF mutations: 
What is the overall pattern of geographic variation? Is variation continuous in space 
suggesting geographic variation or isolation by distance? Are there gradients of variation? 
Etc. Study of the ∆F508 CF mutation indicates a frequency cline from 30% in Turkey to 90% 
in Denmark. Currently this finding is explained by Neolithic expansion from Southern Europe 
to Northwest Europe. The gene mutation may have been retained by selective advantage or by 
isolation or by increased diversity and population change at the point of introduction in the 
Levant or Middle East. Further chapters are devoted to the geography of CF (q.v.). 
Information that has been gathered permits a table to be constructed, which reflects world-
wide frequencies of the more common CF mutations. Table 3 lists this information. It will be 
seen that the ∆F508 mutation represents 66% of mutations world-wide and hence is the most 
frequently found mutation. Table 4 indicates the specific frequencies in various ethnic groups. 
Most mutations are rare, however15. 
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Figure 11 
 
Biosynthesis and function of CFTR in an epithelial cell 
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Figure 12 
 
The fate of the CFTR molecules synthesised on 
endoplasmic reticulum 
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Table 4 
 
Frequency of common CFTR mutations 
world-wide 
 
Mutation % Frequency 
∆F508 66 
G542X 2.4 
G551D 1.8 
W1282X 1.5 
N1303K 1.2 
R553X 0.9 
3849+10kbC→T, 621+1G→T 0.6 
1717-1G→T, R1162X, 1898+1G→A 0.4 
2789+5G→A, R117H 0.3 
G85E, R347P, ∆1507 0.2 
A455E, R334W, s549N, G551S 0.1 
 
After: Knowles MR, Friedman KJ, Silverman LM. 199915   
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Table 5 
 
Frequency of the ∆F508 mutation in different 
ethnic groups 
 
 
 
Group % of CF chromosomes 
White (world-wide) 66 
White (Northern Europe) 70-80 
White (Southern Europe) 50-55 
Hispanic (USA) 48 
Jews (Ashkenazi) 30 
African Americans 48 
Native Americans <5 
 
After: Knowles MR, Friedman KJ, Silverman. 199915
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We have now come full circle. The initial descriptions of the clinical disease can be matched 
with specific organ involvement and specific CF mutations. Davis et al.8 have proposed a 
specific hierarchy of organ sensitivity to deficits in functional CFTR (see figure 13). The 
organ that has the greatest requirement for normal CFTR is the vas deferens. It requires CFTR 
of levels of 10% or more of normal for proper development. The sweat duct is the next most 
sensitive, requiring up to 10% of normal. This is highly relevant to those presenting with CF 
disease and normal sweat electrolytes, as discussed in Chapter 2. Normal sweat duct function 
appears to require more functional CFTR than does normal pancreatic function. The position 
in regard to lung function is more complex. Some patients have lung disease and normal 
sweat electrolytes, while a significant number have lung disease and normal exocrine 
pancreatic function. Severe deficiency (<1%) of CFTR leads to pulmonary, pancreatic and 
sweat abnormalities8. Normal individuals will produce 95-100% full-length CFTR transcripts 
in place in the airway cells. Conversely, those with a severe mutation in one allele and a mild 
mutation such as R117H/5T in the other may end up with 0.75% of normal CFTR activity. 
However, here again this does not always hold true. Massie et al. have shown that compound 
heterozygotes may be pancreatic insufficient but in general24 they are pancreatic sufficient. 
This mutation is rare and does not feature in the common 20 mutations as illustrated in the 
table. Various permutations can be found, therefore. About 8% of A455E CFTR reaches the 
cell surface with full activity, but a person with ∆F508/A455E will have only 4% of normal 
CFTR function. They will have pancreatic sufficiency, high sweat chloride levels and delayed 
pulmonary disease8. 
 
CF is one of the most frequent autosomal recessive and lethal genes in Europeans and 
populations of European descent. Thus, the question is posed as to why the gene remains so 
frequent in these populations, as it would be assumed that those with the disease are at a 
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reproductive disadvantage. In terms of the ∆F508 mutation, about one individual in twenty-
two (1:22) is a healthy carrier of a recessive gene for the disorder.  Romeo et al.16 suggested 
five differing hypotheses to explain this phenomenon viz.  (1) genetic heterogeneity (2) high 
mutation rate (3) meiotic drive (4) heterozygote advantage (5) genetic drift. The genetic 
heterogeneity theory, namely that two or more genes may be responsible for the same clinical 
phenotype, was soon dismissed. This was on the basis of the results of studies on 
consanguinity and linkage studies. Other work has not supported the concept that there is a 
preferential transmission of the CF gene. Thus the idea of meiotic advantage especially via 
fathers has not been sustained nor has a high mutation rate been established.  
 
Wright and Morton17 estimated that with a lethal recessive gene like CF, the probability of 
reaching the incidence observed by chance, in European populations, was in the order of 
0.001. However, for a frequent disease state like CF, there is no direct evidence to support the 
hypothesis that the gene incidence has occurred by chance. The evidence to date points to the 
existence of a specific heterozygote advantage associated with the CF mutation. This suggests 
that the heterozygotes show a slight increase in biological fitness compared to unaffected 
homozygotes. The best understood example of this, to date being the sickle cell trait, where 
relative immunity to falciparum malaria occurs in those who carry the gene and are not 
affected by the full sickle cell disease. 
 
In relation to heterozygotes for CF, one suggestion was that non-carriers were three times 
more likely to develop asthma than carriers18 but this finding could not be substantiated in a 
United Kingdom study of heterozygotes19.  For a disease that has a high frequency only in the 
20th century, it seems most unlikely that this would be the basis of genetic advantage. 
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However, further evidence has been produced to support the asthma relationship without 
establishing any benefit to the individual20. 
 
Until recently, functional evidence supported the hypothesis that CF carriers can withstand 
secretary diarrhoea better than normal persons can. This has been studied using a mouse CF 
model, with the concept that cholera was in the past the most likely disease to produce such a 
situation. However, results from testing with a variety of secretagogues, including cholera 
toxin exposure, have been conflicting21, 22. The concept was based upon the idea that mice 
lacking CFTR protein would not secrete fluid in response to the stimulus, while heterozygotes 
would secrete about 50% of the normal fluid and chloride ion. The reduced fluid loss would 
protect them from death due to the toxic effects of cholera. However, no significant difference 
between heterozygote and homozygote mice could be demonstrated22. Recently, Pier et al.23  
have produced evidence that in the heterozygous state CFTR mutations increase resistance to 
the infectious disease, typhoid fever, due to infection with the organism Salmonella typhi. The 
reason for this is that the organism uses CFTR to enter into the intestinal epithelial cells. Thus 
in the heterozygote, with diminished levels of CFTR, there may be a decreased susceptibility 
to typhoid fever. Interestingly, the group demonstrated that this was organism type-specific 
and that Salmonella enterica or S. typhimurium did not enter the cells in a similar manner. 
The authors further support their argument by saying that despite previous statements, cholera 
did not enter Europe from India until 1832, so it is unlikely to have selected for mutant alleles 
of CFTR. Thus, resistance to typhoid fever could serve as the selective factor for heterozygote 
advantage conferred by the ∆F508 CFTR allele23. 
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Despite the vast new information revealed about the molecular basis of CF, there are many 
unanswered questions. These are highly relevant in finding treatments for the disorder if 
molecular manipulation is to become a practical treatment for the disease. 
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Figure 13 
 
CFTR activity and tissue manifestations of 
CF 
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Footnote: 
In the discussion of mutations, the following terms are defined as below. 
Missense mutations: are single-base changes that result in substitution of one aminoacid for 
another in the protein product of the gene. 
Nonsense mutations: are single-base changes that create one of three termination codons in 
the genetic code (UAA, UAG or UGA) resulting in a shortened, dysfunctional protein product 
of the gene. 
Insertions and deletions: are the addition or the loss of one or more bases can be as much as 
the deletion or duplication of an entire gene. The impact of an insertion or deletion in the 
coding sequence of a gene produces a frameshift. Codons consist of three bases, hence adding 
or subtracting a base changes the coding of all the codons that follow. 
 
Source: http//intouchlive.com/cancergenetics/mutypes.htm
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Chapter 4 
 
 
The United Arab Emirates and the Sultanate of 
Oman 
 
 
“And the night shall be filled with music 
  And the cares that infest the day 
  Shall fold their tents like Arabs 
  And as silently steel away.” 
 
 
The Day is Done 
Henry Longfellow (1807-1882) 
 
The people of the UAE, like those in the rest of the Eastern Arabian Peninsula, are of Arab 
stock. Their antecedents spread eastwards across the peninsula in successive waves of 
migration 2,000 – 3,000 years ago, carrying with them their language and survival skills into 
this new and harsh environment. On arrival at the northern seaboard they mingled with and 
eventually merged with the people already living in the area. These residents were, too, of 
Semitic stock. Inscriptions in their now extinct Semitic language can be found to this day in 
Sharjah (Al Dur) and in Umm al-Qaiwain. However, by the seventh century AD both 
populations had become a homogeneous society with a common Moslem faith1.  
 
 The physical geography of the UAE is immensely varied and ranges from rugged mountains 
to a low mangrove-fringed coastline and from the vast arid desert of the Rub al Khali (Empty 
Quarter) to fertile oases packed with date palms and fruit. The country lies between latitude 
22°30 north and longitude 51° and 56°30 east. To the north and north-west the country is 
bounded by the Arabian Gulf, the Musanden Peninsula enclave of Oman and the Gulf of 
Oman; to the south by Saudi Arabia and Oman; and to the west by Qatar and Saudi Arabia. 
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The Gulf coast consists of salt marshes (sabkha) that give way to inland to desert and gravel 
plain. The Hajar mountains rise to 2,134 metres and form a barrier between the east and west 
coasts. The continental plate upheaval has left brown jagged folds and fissures of limestone 
and igneous rock, which in certain places are rich in fossils, revealing the land’s earlier 
submarine existence. Only 5.5% of the land area is said to be cultivable and only 0.2% is 
actually being cultivated at the moment2. 
 
Prior to their independence and federation in December 1971, the UAE was known as the 
Trucial States, a loosely defined affiliation of the main seven emirates. Six of the federation’s 
seven states share the Arabian Gulf coast, extending east from the base of the Qatar’s 
peninsula for 700 kilometres to the Musanden Peninsula. These emirates from west to east are 
Abu Dhabi, Dubai, Sharjah, Ajman, Umm al Quaiwain and Ras al Khaimah. The seventh 
emirate Fujairah, lies on the Gulf of Oman coast with no direct access to the Arabian Gulf. 
While the current political map of the Gulf has taken shape in recent years, their origins go 
back to the beginning of the 18th century. The people are descendants of the maritime tribal 
groups from the Arabian Peninsula, as discussed earlier, whose traditions dominate the new 
states of the UAE, Qatar and Bahrain2. 
 
Trade and seafaring were the two main occupations of Gulf inhabitants from ancient times. 
The Gulf formed the link between east and west with Gulf traders carrying eastern 
commodities from India and China to the mouth of the Shatt al Arab and from there by 
caravan routes to the Mediterranean. The oldest excavated settlements of the UAE are in Al 
Ain at Jebel Hafit which date back to the 4th millennium BC.  Excellently constructed graves 
have been found on Abu Dhabi Island and the contents of these graves contain pottery and 
copper daggers, which strongly indicate a link with the Indus valley and Baluchistan.  
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Similarly, the concept of the falaj system of bringing water over considerable distances is not 
only found in Arabia but in Iran and Baluchistan. These links with other cultures outside of 
the region remain important to the present population of the Emirates. They have been 
reinforced by tribalism, Islam and current political structures like the Gulf Co-operative 
Council. 
 
The tribal structure is important and remains strong. The Bedouin tribe (al qabilah) is 
composed of clans (al ashirah) which in turn are divided into families (al ailah). The tribal 
pattern of the UAE was probably established in the 2nd century AD. Two major migrations 
into the area seem to have originated in South Arabia, probably in the Yemen.  They first 
came via Oman and through the Hajar Mountains, reaching the Al Ain area around the second 
century AD. Other groups seem to have come via the Nejd and eastern Saudi Arabia, attracted 
also to the well-watered and strategic oases of Al Ain which controlled the passes to and from 
the coast. Later, most of the population of the emirates became settled with the true nomadic 
element of the population being about 10%. The tribal structure was tightly knit by ties of 
marriage characterised by substantial bridal dowries kept within the family. Even today 
consanguineous marriage accounts for over 50% of all marriages3.  There are four main tribal 
groups in the emirate of Abu Dhabi of which the Bani Yas dominates. Over many generations 
the Bani Yas extended its territory into the interior. However, a breakaway branch of the Bani 
Yas, Al Bu Falasah established itself in Dubai. Dubai presents a different picture with a larger 
foreign element within its population.  The position of Dubai on one of the best harbours in 
the Gulf attracted a cosmopolitan population of Baluchis, Persians and Indians. People of the 
Qawasim tribe politically dominated the Northern Emirates. Their interests and power base 
lay in the sea. Immigration from Baluchistan and Persia also took place for the same reasons 
of geography and trade 3. 
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The total population of the UAE stood at 2.624 million in 1997. The annual increase has been 
in the order of 100,000 with 41,893 births occurring in 1997. The additional numbers being 
made up by those on residential permits for work and their dependants. Abu Dhabi Emirate 
accounts for 1.017 million and Dubai Emirate 757,000 of the population with Sharjah 
(439,000) having the only other significant population centre. The population pyramid 
indicates an excess of young adult males. This is accounted for by the importation of young 
men without their families on short-term work- related visas. They are in the main from 
Afghanistan and the Indian subcontinent. Young people below the age of 14 years account for 
26.3% of the total population4. There is a normal sex distribution in this age range reflecting 
that, in the main, they represent UAE nationals. The critical statistic is the proportion of the 
total population, which is of UAE nationality. This figure is not officially available nor is it 
available in any publication or from the census data, although the information is collected in 
each census. The stated reason for this is security. The information gained from unofficial 
samples and observations is that the ex-patriate workforce represents about 75% of the 
population. There have been no major efforts to “Emiratise” the workforce in the immediate 
past, unlike countries such as the neighbour, Oman. The mean size of UAE families is seven 
children, thus in the immediate future major demographic forces will be in play. The other 
important factor will be economic and oil prices this determines whether the country can still 
afford to import labourers for unskilled jobs5.  
 
Thus, when we are discussing the gene pool in relation to CF we have been dealing with 
approximately 750,000 people, of whom the overwhelming majority are of true Bedouin 
origin. There has been little naturalisation, as the rules require a fluent knowledge of the 
Arabic language, to be of the Moslem faith and not to represent a political threat. 
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The Omani culture has its roots in the Islamic religion. Oman developed, however, its own 
form of Islam which is called Ibadhism, It is named after its founder Abdullah ibn Iba who 
lived during the 7th century AD. Oman is a tolerant state and unlike some if its neighbours 
permits others to practice their religion. Like the UAE, the history of Oman dates back many 
thousands of years. In biblical times, the country was the hub of the frankincense trade. Its 
strong seafaring traditions led to the development of an empire ruled over by the Sultans of 
Oman that spread from Zanzibar to the tip of the Indian sub-continent5. This empire reached 
its heyday in the late 16th century. Subsequently the country's fortunes declined, reaching a 
nadir in the 1950s. At this time the country was impoverished and the then Sultan Said bin 
Tamur adopted an isolationist policy. After further political trouble and the incursions of 
Marxist forces from South Yemen, Sultan Qaboos, the Sultan’s son, overthrew his father in a 
bloodless coup. The country was rebuilt, the rebels suppressed with the aid of British forces 
and the economy restructured using the countries oil revenue. Subsequently, the country has 
been opened up and became a member of the Gulf Cooperative Council. The current 
population of the country is 2.325 million. 
 
The Sultanate occupies the south-eastern tip of the Arabian Peninsula. Oman is bounded by 
sea on two sides, the Gulf of Oman to the northeast and the Indian Ocean to the southeast, 
resulting in a coastline of 1062 miles. The total land area is approximately 309,500 square 
kilometres and is the third largest in the Arabian Peninsula.. The land boundaries are with the 
Kingdom of Saudi Arabia and the Republic of Yemen to the west and the UAE to the north. 
The country is predominantly open desert with gravel plains and sand. There are two large 
mountain ranges. The Hajar range dominates the north with the highest peaks reaching 3075 
metres. Dry river valleys (wadis) heavily dissect the upland region. However, these easily 
flood after winter storms. Between the Hajar Mountains and the sea lies a narrow fertile strip. 
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It is within this strip that the majority of the country’s population live. The southern province 
of Dhofar is also dominated by the coastal mountains which help capture moisture from the 
summer monsoons. A fertile strip of land lies adjacent to the region's capital, Salalah. 
 
The climate is hot and humid at the coast in summer and inland it is hot and dry. The 
mountains enjoy a moderate climate throughout the year. The north has an average 
temperature in the summer of 32-48°C. In the south, the temperature, all year round, ranges 
between 30-35°C6. 
 
In relation to specific health matters, at the time of the accession of Sultan Qaboos, the 
country was in a sad state. There was one 23 bedded Mission Hospital and only one Omani 
trained doctor. Over the next twenty-five years, 51 hospitals had been established and over 
115 health centres. Two tertiary level hospitals had been established in Muscat and the health 
system has expanded has become increasingly more sophisticated. There is an increasing 
proportion of the health workforce of Omani nationality7. This has been achieved with the 
continued rapid growth and success of the health system in Oman. To educate the indigenous 
population and to be self-sufficient in professional staff a medical school had been established 
in Muscat at the Sultan Qaboos University. Currently, about 80 new doctors graduate 
annually. Major inroads have been made into the health problems of the country. Mass 
immunisation schemes have been successful with a 95% coverage and a tuberculosis control 
programme is in place. The health services have improved to the extent that acute infection 
and malnutrition have been overcome and are no longer a major problem, such that the 
presence and management of inherited disease becomes a worthwhile future goal in Oman. 
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Figure 14 
 
Near Nizwa, Oman 
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Chapter 5 
 
Cystic fibrosis in the Middle East: the Historical 
Perspective 
 
 
“Lives of great men remind us 
 We can make our lives sublime 
And, departing leave behind us 
Footprints in the sands of time” 
 
A Psalm of Life 
Henry Wadsworth Longfellow (1807-1822) 
 
 
Twenty years after the definition of cystic fibrosis (CF) as a specific disease, the first report of 
an affected Arab child was made in 19581.  This report came from the Lebanon and, four 
years later, a further three Arab children were described from the same centre in a paper that 
included an up-date on the condition of the original patient2.  Pedigree analysis, in one child at 
least, indicated that the family has been of pure Arabic origin for the previous four 
generations.    
 
The recent discovery of over 1000 mutations of the cystic fibrosis transmembrane regulator 
gene (CFTR) has cast new light on the patterns of recognition of CF in the Middle East.  I 
have reviewed, but not cited all, the indexed medical literature and some non-indexed papers 
to gain an historical perspective and insight into the recognition and definition of this 
important disease as it affects Arab communities. 
 
Following the initial report, there was a dearth of information and reports for the next twenty 
years until sporadic reports began to appear from Iraq, Israel and Kuwait3-5.  In 1981, Al 
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Uwihare from Kuwait commented that, in two patients, the condition was not suspected 
before death and the disease was not considered to occur in the Middle East5.  This prompted 
a brisk response from Katznelson6, suggesting that CF was not rare among the Jewish 
population of Israel and that it was very common among the Arabs of Israel.  His contention 
about the Arab population has not been sustained in the subsequent literature.  While the 
original report of CF in an Arab child came from the Lebanon, the most recent report from 
that country has thrown considerable light on the situation there.  Lebanon, being the 
crossroads of the Middle East, has experienced an influx of people from many different areas.  
Desgeorges et al7 have identified twenty families living in Lebanon for several generations, 
who have had at least one child with CF.  They reported on the religious and community 
backgrounds of the affected families (Maronite, Greek Catholic, Shiite and Sunnite) and 
showed that ten different DNA alterations - including two novel mutations - accounted for 
88% of the CF alleles there.  Delta F508 was found in 37.5% of alleles.  Four mutations 
remained unidentified.  
 
CF was first reported in Jordan in 19848, when 12 patients were reviewed retrospectively, 
some having been diagnosed only at post-mortem.  Nazer9 in 1985 felt the prevalence was 
underestimated due to lack of awareness, consanguineous marriage and poor diagnostic 
facilities.  He attempted to define the prevalence rate by studying 7,682 neonates from ten 
different hospitals by the meconium albumin method.  Three infants were confirmed positive, 
by sweat test analysis, which resulted in an incidence of 1 to 2,560 live births. 
 
Following the initial observations in Kuwait that CF existed in that country5, Kollberg 
reported that 17 patients of assorted nationalities had been seen in Kuwait in a fifteen-year 
period11.  Eight were Kuwaiti and three were from other Arab countries.  Kollberg made 
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similar comments to those of Nazer from Jordan, in that the diagnostic facilities for CF were 
not easily available, the diagnosis was not often considered because of a low frequency of the 
condition and that the clinical presentation may be atypical.  Despite this, he commented that 
with a birth rate of 50000 infants per year (population 1.3 million) and based upon the number 
of infants with meconium ileus, the incidence in Kuwait should be around 1 to 3500 births per 
annum.  Three siblings with CF were reported from Kuwait in 198712.  While being Arab, 
however, the patients were the children of a Jordanian family.  The diagnosis was confirmed 
by very high levels of sweat chloride, with results that were well over 100 mmol/L.  Another 
Jordanian child living in Kuwait presented with metabolic alkalosis and electrolyte 
disturbance and was reported by Issa et al13.  The authors further supported the contention that 
the classical disease presentation may be different in very warm climates where an 
unexplained metabolic alkalosis and prolonged neonatal jaundice should raise the suspicion of 
CF.  Finally, three further children with an atypical presentation and metabolic alkalosis were 
reported from Kuwait14.  Only one child was a Kuwaiti National and the others were 
Palestinian Arabs.  The high summer temperatures, (around 45oC) with high humidity and 
insufficient salt intake were felt to be the key factors in the summer presentation of these 
children. 
 
In the first report from Bahrain, Khan and Mohammad15 described, in 1985, eight children 
with proven CF from Bahrain.  They suggested that it was the largest number, to date, of CF 
patients reported from an Arabian Gulf state. Five of the children were products of 
consanguineous marriages, there being two brother and sister pairs, and two of the families 
were closely related. It is not specifically stated that the patients were Bahraini nationals, 
however.  The most recent documentation of CF from Bahrain was in 1998 when 25 patients 
with proven CF were described16. The authors attempted to define the incidence, phenotype 
 79
and outcome of the disorder in Bahrain.  The reported patients were drawn from an 18-year 
period and the authors concluded that the incidence is 1 in 5,800 and the prevalence is 3 in 
100,000.  In 80% of cases, the patients had been products of consanguineous marriages - in 
contrast to the normal consanguinity rate of 39% in Bahrain.  They reported further that the 
spectrum of clinical presentation of the disease is severe in that country.  Meconium ileus was 
present in about 20% of these patients.  It was noted, however, that there has been a steady 
fall in the age-related mortality from CF there, which was attributed to improved living 
standards and medical care in Bahrain.  Increased awareness among medical professionals 
about the disease and its management was advocated as an additional beneficial factor.   
 
Saudi Arabia, a large and populous Arab state, has produced, as one would expect, more 
literature on CF in Arabs.  Surprisingly, the first identification did not occur until 1985, when 
a seven month old Saudi child was shown to present with the classical features of recurrent 
respiratory infection, diarrhoea and failure to thrive17. It was noted that the child came from 
the ‘Unooz’ tribe, who are located in northern Saudi Arabia (near to the border of Jordan and 
Iraq), an area already established as one in which CF was known to exist with some 
frequency.  Nazer and colleagues18 in 1989 commented that the CF gene was believed to be 
rare, or non-existent, in Saudi Arabia.  They, however, were able to find thirteen Saudi 
children who had elevated sweat chloride levels and typical clinical histories suggesting CF.  
The principal author, Professor Nazer, had previously described CF in Jordan9. He speculated 
that the majority of patients with CF in Saudi Arabia are undiagnosed and die in infancy or 
early childhood. To support this argument he showed that in the seven families reported by 
his group, four siblings had died of CF-like symptoms within their first year of life.  Their 
contentions are well supported by the subsequent flow of information about CF from Saudi 
Arabia. Three further patients from the Eastern Province were presented with intestinal 
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obstruction, intussusception and meconium ileus, secondary to CF19.  Again, a further ten 
children from the Eastern Province were documented as having CF in 1991 and Mathew et al 
suggested an incidence of 1 in 4,243 for Saudi children20. Again, as previously described in 
Kuwait, vomiting and metabolic alkalosis associated with the high ambient temperatures in 
the summer months were associated with the presentation in these patients.  A review by 
Nazer and Rahbeeni21 of their experiences of CF included 36 patients seen by them over the 
period 1986 to 1992.  Emphasis was placed on the hepatic presentation of the disease and on 
the fact that CF was relatively common there and associated with serious sequelae.  
Hepatomegaly, jaundice and possible glycogen storage disease were the main referral 
diagnoses.  It was postulated that the CF mutations, which give rise to hepatic disease 
manifestations, might be different to others that have previously been described.  A clinical 
description of a further ten Saudi children was published in 199522.  It was suggested that 
while the common presentations of the disease occurred in Saudi, rarer forms had to be 
considered.  Eight of the children had the complex of metabolic alkalosis and hyponatraemia 
(Pseudo-Bartter Syndrome), while vitamin E deficiency or gallstones or nasal polyps were 
present among the others.  In keeping with the changing knowledge of CF brought about by 
molecular genetics research, the two most recent publications from Saudi Arabia23, 24 
concentrated attention upon the CFTR mutations, which may occur in Saudi children.  Over 
85 children have been identified and attempts have been made to determine the responsible 
mutations.  In one group of 15 patients, six different mutations were identified, of which two 
were novel23.  In the larger series of 70 patients, mutations were identified in 42 patients.  Six 
novel and six known mutations were reported.  The difference between these two studies is in 
that the study of El Harith et al23 was drawn from the population of the Eastern Region of the 
country.  Banjar and Mogarri, who provided the largest series of Arab CF patients, published 
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the most recent clinical overview of Saudi CF patients.  An important finding was that median 
survival was 10.9 years compared to 32 years in North America24. 
 
The pattern of sporadic case reports followed by more detailed studies also applies to CF in 
the United Arab Emirates (UAE).  The first patient described, in 1987, was a UAE citizen of 
Baluch descent, who presented with diarrhoea, cough and repeat respiratory illnesses26.  The 
second account, again from a Northern Emirate, involved a newborn with meconium ileus and 
a five-year-old child who developed an intussusception.  The latter patient, however, had no 
confirmatory tests performed and the diagnosis was based on clinical suspicion of CF27.  
Subsequently, further clinical reports and molecular studies occurred in the Emirates28, 29,30.  
Later, the common CF mutations in the UAE were identified31.  It was reported that two 
mutations, ∆F508 and S549R (T→G) account for 46 out of 52 (88%) CF alleles and 
characterise 95% (18 out of 19) of the affected families that were investigated.  Furthermore, 
these two mutations are segregated in the UAE population according to ethnic background: 16 
CF patients (who were of true Bedouin origin) were S549R (T→G) homozygotes and 7 
patients (who were of Baluch lineage) were homozygous for ∆F50831. 
 
Review of the history of CF in the Middle East provides recognition and development 
patterns.  The general recognition of the disease in the area came some 40 years after the 
original clinical definition in Switzerland and the pathological definition in the United States.  
Many of the authors allude to the general lack of awareness of the disease in the Middle East 
and to the lack of diagnostic facilities, such as sweat chloride determinations.  Despite this, 
pioneers such as Nazer in Jordan9 and subsequently in Saudi Arabia18, were able to screen 
some populations and provide some information about CF incidence and prevalence.  With 
the burgeoning new knowledge of the CF gene and its mutations from the late 1980s, together 
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with the mounting prosperity in the Gulf Region and the upgrading of medical facilities, a 
new era has dawned.  It became clear that the classical presentation of the common mutation 
∆F508 did not characterise all mutations and that, in most of the region, other presentations 
occur.  We have noted the predominance of hepatic disease in Saudi, electrolyte disturbances 
from Kuwait and the rarity of meconium ileus associated with CF in countries such as the 
UAE.  The ever-increasing number of mutations being recognised from Saudi Arabia and the 
Lebanon (many of these being novel mutations) reflects on the characteristics of these 
societies.  The Lebanese findings reflect the coexistence of numerous communities, who tend 
to have their own range of mutations, showing little mixing between the groups (Table 6).  
Consanguinity in all of these Arab countries (consanguinity was found in 80% of families 
with CF members in Bahrain) must be a major factor in perpetuating many of the rare 
mutations, as clearly illustrated with the example of mutation S549R (T→G) in the UAE.  
The ethno-history of CF is just becoming unravelled and the tracing of these various 
mutations in diverse ethnic groups gives a fascinating insight into the patterns of population 
migrations throughout history. 
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 Table 6 
 
Important milestones in clinical and mutational 
findings in CF in the Middle East 
 
COUNTRY YEAR AUTHORS NO OF 
 PATIENTS 
MAJOR CFTR 
MUTATIONS 
LEBANON 1997 Desgeorges et al(7) 20 ∆F508 
W1282X 
N1303K 
UAE 1997 Frossard et al (30) 17 S549R 
∆F508 
JORDAN 1984 
1992 
Kamal et al(8) 
Nazer(10) 
12 
3 
- 
- 
BAHRAIN 1998 Al-Mahroos(16) 25 - 
SAUDI 
ARABIA 
1998 
 
 
 
1998 
 
 
 
 
 
1999 
El-Harith et al(23) 
 
Dork et al(33) 
 
Banjar et al (24) 
 
 
 
 
 
Banjar et al(32) 
 
15 
 
 
 
70 
 
 
 
 
 
70 
 
3120+1G→A 
N1303K 
1548delG 
 
∆F508 
I1234V 
N1303K 
R553X 
3120+1G→A 
 
H139L 
S549R 
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Chapter 6 
 
 
 
The Geographic Distribution of Cystic Fibrosis 
Mutations Gives Clues about Population 
Origins 
 
 
“The dust of creeds outworn”   
Prometheus Unbound, 1,697 
 
Percy Bysshe Shelly (1792-1822) 
 
 
The founding of the CF Genetic Analysis Consortium in 1989 has fostered extraordinary 
advances in the molecular genetics of CF.  At this time, the Consortium has compiled over 
1000 DNA variations (mutations and other sequence alterations) scattered throughout the 
CFTR gene and responsible for the various forms of CF1.   The most common alteration that 
leads to abnormal CFTR is that resulting in the loss of a phenylalanine at position 508 of the 
CFTR protein; hence its designation as ∆F5082.  ∆F508 frequencies vary from 87% in 
Northern Europe to 28% in Asia (Middle East), while its combined world-wide frequency is 
66%1. 
 
Other mutations are rarer but their frequencies are quite variable amongst different ethnic and 
geographically located populations1.  In some populations, a few mutations only (three to six) 
account for 60-90% of all CF chromosomes; many more rare mutations, however, have to be 
detected to characterise all CF chromosomes.  
 
This information is presented to support the hypothesis that this knowledge is important and 
has direct applications include genetic counselling, prenatal diagnosis, and genotype-to-
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phenotype correlations allowing one to evaluate an individual’s prognosis and give 
appropriate patient management.   Information gained nationally, regionally and world-wide 
has also permitted geographic (synthetic) maps to be produced for many countries.   Such 
maps are useful in shedding light and making inferences about natural selection gradients, 
local gene flow, recent and historical population migration patterns, and about the 
characteristics of human populations and ethnicities. 
 
I present here population genetics data that has been gathered about the ∆F508 mutation and 
information with regards to two other common mutations, namely G542X and N1303K.   
Furthermore, mutation -3120+1GA casts new light on populations of African descent and 
allows us to probe whether there is a single origin for a commonly shared mutation. 
 
 
 
∆F508 
Morral et al3 studied microsatellite haplotypes for ∆F508 and normal chromosomes and 
demonstrated that the ∆F508 mutation occurred at least 52,000 years ago.  This event took 
place in an ancestral population that expanded and spread the ∆F508 mutation.  Other genetic 
markers suggest that the mutation was present in the humans who entered Europe 
commencing some 40,000 years ago bringing with them the culture and life of the Upper 
Palaeolithic period4.  Following the initial introduction, further expansions occurred at 
differing periods and it is thought that the spread into Europe was in a wave pattern.  
Evidence for this is based upon the differing geographical frequencies of different haplotypes 
associated with ∆F508.  The theory of an advance through Europe in a wave formation has 
been promoted and supported as a concept by the finding that there has been genetic 
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replacement in the area of Central Europe, at a later period, by relatively recent immigrants of 
a different genetic background3. 
 
There is throughout Europe a south-east to north-west gradient of frequency for the ∆F508 in 
keeping with the concept of human spread across Europe starting from the Middle East.  
Further work was carried out to establish a more detailed map of the mutation and its 
frequencies in Europe5, 6. Once again the gradient was confirmed and reinforced by data from 
several towns or regions within each country.  Denmark was confirmed as having a frequency 
of the mutation of 87%, while in the Faeroe Islands ∆F508 accounts for 100% of CF 
mutations.  Istanbul, Turkey had the lowest frequency at 27%.  This distribution was based on 
the analysis of 17,886 CF chromosomes. 
 
The concept proposed is that the lower frequencies of mutation observed in the southern 
European populations are the result of a greater genetic heterogeneity in the southerners.  In 
addition, other markers on the chromosomes suggest that the ∆F508 mutation was introduced 
more recently into northern Europe than into the southern part of the continent.  Thus, as 
stated earlier, the spread throughout Europe was a result of migration of early farmers during 
the Neolithic Period (i.e. Indo-Europeans).  However, a puzzling aspect to this is that there is 
a very high frequency of ∆F508 mutations within the Basque Region between France and 
Spain, where frequency rates are as high as 87%.  The Basque people are one of the oldest 
populations in Europe and it is suggested that they are derived from people who became 
established in the late Palaeolithic period.  Their language (Euskera) is a pre Indo-European 
language that has survived despite successive waves of colonisation of neighbouring areas.  
This hypothesis was tested by Casals et al7 who studied intragenic markers which indicated 
that, indeed, the ∆F508 mutation was not spread by Indo-Europeans to the Basque Region, 
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but was already present in Europe during the Palaeolithic Period and prior to the arrival of the 
Indo-Europeans.  Thus the Basque population probably represents the oldest settlement in 
Europe carrying the ∆F508 mutation and probably comes from a different population root.  
When further expansion and migration of people into Europe occurred there was little 
introduction of other CF mutations into the community and hence there occurred an increased 
frequency of ∆F508 within the Basques compared to other nearby communities.  An 
alternative hypothesis is that the Basque population acquired the mutation from the Indo-
European migrants and the high gene frequency was due to genetic drift and selective 
homozygote advantage in this close and formerly isolated community8.  However, Casals et 
al7 findings favour the fact that the mutation was already in Europe in the Palaeolithic 
population of which the Basques are the most homogeneous relic population.  Further, the 
subsequent Neolithic migrations diluted the frequency of ∆F508 mutation in some 
populations by bringing other mutations into Europe7.  In the Basques this probably did not 
occur due to factors such as isolation, linguistic cohesion, climate and in that their territory 
was not deemed attractive for the agricultural aspirations of the new migrants. 
 
Further evidence to support the ancestral population concept comes from the studies of de 
Braekeleer et al who studied the Celtic population of Brittany9.  The population in Brittany 
has one of the highest CF rates (1 in 1600 live births) and is characterised by low 
immigration, high consanguinity and cultural and linguistic isolation.  The original Celtic 
people settled in Brittany in the 4th century having sailed from Ireland.  The study of 
microsatellite haplotypes in this population would be expected to be similar to that of Ireland, 
but different to that of Spain and Italy.  However, the findings of de Braekeleer et al9 showed 
that the three most frequent haplotypes of ∆F508 chromosomes are the same as those found in 
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Ireland, Spain and Italy.  This then provides further evidence that these haplotypes were 
associated with an ancestral population from which all four populations are descended.  
 
G542X 
G542X, a nonsense mutation, is the second most common mutation after ∆F508.  It results in 
failure of CFTR protein production.  Evidence suggests that it arose as a result of a single 
mutational event9.  The mutation accounts for 2.4% of CF mutations worldwide, but as with 
other mutations, its frequency varies geographically10.  Kerem et al described the G542X in 
their major paper on the identification of the CF gene2.  Lucotte and Hazout11 have described 
the distribution of this mutation throughout Europe.  The highest frequency was found in 
Spain (8.8%) and Italy (10.9%) with a high percentage of all CF mutations being found in 
Macedonia and the Slovak Republic.  Loirat et al12 have developed further the frequency 
distribution pattern of the mutation showing it to be lower in north-eastern Europe compared 
with south-western Europe and very high in Turkey, the Canary Islands and with the highest 
frequency of all in Tunisia.  They have produced a fascinating hypothesis that the areas with 
an elevated frequency of the G542X mutation correspond to ancient sites of occupation by the 
occidental Phoenicians.  They postulate that the mutation was introduced into Spain by 
Phoenicians (from Carthage), hence the relatively high frequencies observed in Tunisia 
(Carthage), the Canary Islands, Sardinia and Sicily.  The initial intrusion by the Phoenicians 
occurred between 2,500 and 3,000 years ago.  Thus the evidence to date suggests that the 
G542X mutation may provide another link in the story of the spread of the CF gene mutations 
and in the definition of their geography13. 
 
N1303K 
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This is a missense mutation, which results in the CFTR being prevented from reaching the 
epithelial membrane.  The frequency of the N1303K allele varies significantly between 
countries and ethnic groups.  It has a higher relative frequency in the Mediterranean region 
and in the north of Africa and the south of Spain suggesting that it was introduced into Europe 
through the Iberian Peninsula14.  Microsatellite markers indicate that the mutation is about 
35,000 years old (similar to G542X) and again diffusion through Europe from an Asian origin 
is suggested by these recent findings14.  Further, it is one of the six frequent mutations found 
among Ashkenazi Jews and results in a severe form of CF5.  Severe disease is associated with 
the mutation and in particular, pancreatic disease.  No correlation could be found between the 
mutation in heterozygous or homozygous states and the severity of the lung disease15. 
 
“Out of Africa” - 3120+1G→A Mutation 
Cystic fibrosis has been regarded as rare in the black population of Africa17.  CF mutation 
studies were carried out on three patients in South Africa in 1996.  These studies revealed that 
one patient was homozygous for the 3120+1G→A mutation and the other two were 
compound heterozygotes for 3120+1G→A/G1249E and 3120+1G→A/3196 del 5418.  The 
mutation 3120+1G→A was first described in three African-American CF patients and 
subsequently found in 12% of African-American CF chromosomes, but if mutations found in 
white populations were excluded the figure rose to 53%.  The mutation was found in the 
father of one patient who originated from Cameroon and proved to be a carrier for 
3120+1G→A18.  Again, this mutation was found to be the predominant CF mutation in the 
Eastern Oasis population of Saudi Arabia19 and in addition three Greek CF families have been 
found to have the mutation.  Dork et al19 have attempted to find out if the CF mutation in 
these three diverse populations has a common origin.  They analysed DNA samples from 
African-Americans, Greeks and native Africans (South Africa and Cameroon).  All three 
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groups carried 3120+1G→A mutations as confirmed by sequencing.  Three highly 
informative CFTR microsatellites in intron 8 and 17b were examined.  The analysis indicated 
that the mutation was most likely to have been derived from a common ancestor.  In the case 
of African-Americans, this is not surprising as the group originated from West Africa between 
the 16th and 19th centuries.  The Saudi patients are less easy to explain, as the authors state 
that the families were not anthropomorphologically of African descent19.  However, a 
continuous gene flow between Arabia and Africa has been present for many centuries in 
association with trade and the spread of the Islamic religion. 
 
The findings in the Greeks also were difficult to explain, as they are the only Caucasian 
population who have had the 3120+1G→A mutation identified.  There are, however, rare 
mutations shared between Saudi Arabs and Greeks such as a polyadenylation-signal mutation 
in the α-globin gene in thalassaemia patients.  It is postulated that historic contacts between 
the Greeks and Saudis such as that of Alexander the Great or the ancient Minoan civilisation 
may be the source of contact, which linked these populations with the ancient CF mutation of 
Africa15. 
 
Conclusion 
The commonest CF mutations in Europe and one rare African mutation arose as the result of 
initial founder effects that seem to have occurred between 30-50,000 years ago.  The current 
spatial distribution of these mutations appears to reflect some of the history of population 
migrations. The survival and spread of these mutations adds weight to the “gene advantage” 
hypothesis, whereby CF mutations may have conferred selective advantages be they against 
cancer, typhoid or against any other diseases that yet remain to be identified. 
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 Chapter 7 
 
 
Cystic Fibrosis in the United Arab Emirates: 
Initial Clinical Observations 
 
 
 
“When sorrow come, they come not single spies 
 But in battalions” 
 
Hamlet  IV v78 
William Shakespeare (1564-1616) 
 
 
The paucity of information on CF in the UAE must be viewed in the light of the health 
services development in the country during the last century. Indeed, at the beginning of the 
20th Century, the then Trucial Coast/ Trucial States or Trucial Oman as the country was 
variously known, was dependent on locally practised folk medicine. Early in the 20th Century 
visits were made by missionaries who provided the initial contact with Western medicine. The 
lack of organised medical care in the region has been attributed to the hesitant or suspicious 
attitudes of the people, the erratic nature of contact and the probable disinterest and neglect by 
the British Government1. In due course the British agent in Bahrain was able to provide some 
medical services for the people of the Gulf Emirates. An outbreak of smallpox in the 1930s, 
followed by a cholera epidemic encouraged some vaccination against smallpox, the cost of 
which was underwritten by the British Government. It was, however, the impact of the 
smallpox deaths (about 600) which finally was the incentive for the British authorities to 
introduce some form of medical services and the development of health awareness among the 
local inhabitants. Since independence there have been great efforts made to establish modern 
and sophisticated health facilities, with modern hospitals and the latest technical advances. In 
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1993 the culmination of these efforts saw the first graduates from the UAE University 
Medical School take their place in the medical workforce.  
 
Section I 
As outlined in the Introduction, the identification of an eight-year old Emirati girl with CF 
prompted the eventual establishment a tertiary level consulting clinic for children with 
chronic respiratory disease in 1993. This was run as part of my role as Professor and 
Chairman of the Paediatric Department of the UAE Medical School, and the clinic was based 
at Tawam Hospital, Al Ain, a University associated hospital. It was open, however, for 
referral of national children from any of the seven Emirates. It formed part of the Medical 
Services offered by the staff of the Medical School to the whole UAE. All practising 
Paediatricians in the country had been informed of this service.  
The steady referral of children with chronic respiratory disease permitted the study of the 
causes of such disease. Early recognition that bronchiectasis in children was the commonest 
cause of referral took place2, 3. It was clear, however, that several children who were Bedouin 
Arabs had the features of cystic fibrosis. The disease had never been recognised to occur in 
those of Bedouin descent before in the UAE. The clinical details of the first eight Bedouin 
children diagnosed as having CF are presented below.
 
 Patients and Methods 
 
Eight children who had been referred to the Respiratory Clinic at Tawam Hospital, Al Ain, 
UAE with a history of recurrent respiratory illness and or failure to thrive and have been fully 
assessed and investigated are described. Data regarding birth history, demographic 
information, prior illnesses, ethnic and tribal background and recent clinical features were 
obtained for each patient from the parents and the notes of the referring doctors. 
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The following investigations were carried out: sweat chloride electrolyte levels, serum 
electrolytes, stool chymotryptic activity, full blood count, vitamin E, A and D measurements 
and venous blood for DNA analysis. The sweat electrolyte analysis was measured in each 
patient by the pilocarpine iontophoresis method. 
Radiological assessment was by chest film and subsequent computed tomography as indicated 
by the initial chest films. Respiratory function tests were carried out on the one patient who 
was old enough to perform the tests. The normal clinic weight and height measures and 
sputum or cough swab collections were performed. 
 Based upon the above findings and a full clinical examination, an assessment was made of 
the degree of pulmonary or intestinal disease present in each patient. 
 
Results 
 
A summary of the main details of the patients is given in Table 7 and an overall clinical 
assessment. All the children had strikingly elevated sweat test results with a mean sweat 
chloride level of 110 mmol/L (sd ± 25.95, range 80-155 mmol/L). Meconium ileus had not 
been present in any of the patients, nor were mucus plugs reported in the newborn period. All 
families were of Bedouin descent and belonged to the tribal groups of the Abu Dhabi Emirate 
of the UAE. 
 Pulmonary disease was variable, with one child presenting with gross cor pulmonale (patient 
5), while patient 6 presented early and had no clinical lung disease and a normal chest 
radiograph. Patients 3 and 4 are siblings, as are patients 5 and 8. All patients had 
malabsorption and pancreatic disease. Subsequent to diagnosis, all patients received 
pancreatic enzyme supplements, vitamins, nutritional advice and support in the form of a high 
calorie diet. Appropriate antibiotic regimens were commenced based upon the degree of lung 
disease and the organisms isolated. 
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Comment 
 
All these patients have severe disease. The youngest had no chronic lung disease but marked 
malabsorption. All had the raised sweat chloride levels and malabsorption with very low or 
absent stool chymotryptic activity. None of the eight children had a history of meconium ileus 
at birth. 
As in many Islamic countries, the UAE society is a very private one and personal details 
about families and their background are hard to acquire. In many towns, streets do not carry 
names or numbers and the follow up of patients is difficult. Thanks to her personal charm and 
local nationality, one of our staff was able to interview the families and learn about their tribal 
background. In addition, the full name of each patient helped to identify which of the families 
of the tribe they belong to. Thus it is felt that beyond doubt that we had demonstrated the 
presence of CF in the Bedouin Arabs of the UAE. This is, therefore, the first report of such an 
event and suggested that the disease presentation was not mild. A
                                                          
A This section formed the basis of the paper: Cystic Fibrosis in the United Arab Emirates: I Clinical 
presentation4 
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Table 7 
Summary of Patients’ Clinical Details 
 
 
 
 
Number Sex Age 
(years) 
Pulmonary 
Disease 
Intestinal 
disease 
Sweat Chloride 
mmol/L 
Meconium 
 Ileus 
1 Male 3.5 ++ + 133 Absent 
2 Male 6 ++ ++ 95 Absent 
3 Female 2 ++ ++ 150 Absent 
4 Female 6 + ++ 110 Absent 
5 Female 6 +++ ++ 155 Absent 
6 Female 1 0 ++ 120 Absent 
7 Female 2 + ++ 80 Absent 
8 Female 9 + ++ 110 Absent 
 
 
0     = absent  
+     = present 
++   = severe 
+++ = very severe 
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Section II 
Corresponding to the initial detection of eight Bedouin children with CF, there was a rapid 
expansion of the numbers of children referred to the respiratory service from outside our base 
in Al Ain. Within a one year period a further 12 children were given a diagnosis of CF. The 
clinical assessment and presentation of these additional children is documented in this second 
section. This data and their diagnosis formed the basis of a paper to alert Paediatricians in the 
UAE and Gulf States to the presence of the disease and to reflect upon its severe clinical 
presentation.  It is considered that CF was an under-recognised condition in the UAE. 
 
 
Methods 
The study involved all patients of UAE nationality who were seen at the Paediatric 
Respiratory Clinic or the children’s wards of Tawam Hospital, Al Ain, UAE and to whom a 
new diagnosis of CF was given. The review period was from the 1st August 1993 to 31st July 
1994. All patients were seen and reviewed by me personally and had sweat tests performed by 
the pilocarpine iontophoresis method. Demographic and clinical data were abstracted from the 
medical records. All the children had similar investigations to those children described in 
section I. An assessment was made as to their clinical severity based upon the examination 
and laboratory and radiological tests. Stool chymotryptic activity was measured by the 
method of Kaspar et al.5. The mode of presentation for each child was recorded. 
 
Results 
Twelve children had a diagnosis of CF made within the one-year period. There were 10 
females and 2 males. Their mean age was 3.7 years (SD ± 2.4 years, range 6 months - 8 
years). All families were of Bedouin Arab decent. Their clinical details are summarised in 
Table 8. Sweat test analysis gave a mean sweat chloride level of 107 mmol/L (SD ± 27.33 
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mmol/L, range 75-150 mmol/L). Three pairs of siblings were identified from index patients, 
but all had serious undiagnosed disease by the time of their identification.  
Eleven of the children had significant lung involvement. The second youngest patient, who 
presented at one year of age, had at that time no major lung involvement, however. 
Conversely, the youngest child had extensive lung disease at the time of identification.  
All patients had marked growth retardation and were malnourished. Weight percentiles were 
all below the fifth percentile with the majority below the third percentile. No patient had a 
history of meconium ileus, rectal prolapse or meconium ileus equivalent. None had presented 
with heat exhaustion or salt depletion in the past. In all the children, at the time of their initial 
clinic review, the levels of stool chymotrypsin were all below 2.65 units/G5.  Molecular 
genetic studies have been performed and are reported in Chapter 8. 
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 Table 8 
Summary of Clinical Information 
 
 
Patient Age (years) Mode of presentation 
 
Pulmonary disease Gastrointestinal disease   
       
       
       
       
      
       
       
       
       
       
       
Sweat chloride mmol/L Sex
 9 4 RRI ++ + 133 M 
10 6 RRI+FTT ++ ++ 95 M
11 6 FTT + ++ 110 F
12 2 SS ++ ++ 150 F
13 6 RRI+FTT ++++ ++ 155 F
14 1.2 FTT ++ 120 F
15 2 FTT + ++ 80 F
16 2 FTT+RRI + ++ 110 F
17 2 FTT + ++ 90 F
18 8 FTT ++ ++ 80 F
19 5 SS/RRI/FTT +++ ++ 75 F
20 0.6 RRI/SS/FTT ++ ++ 90 F
 
RRI = repeated respiratory infection 
FTT = failure to thrive 
SS = sibling screening 
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 Comment 
 
No estimate of the extent of the disease nationally can be made from this referral 
pattern. Some of the children of wealthier or more influential families are treated 
abroad for their chronic lung disease. Personal communication with Paediatricians in 
the Hospital for Sick Children, Great Ormond Street, London, UK has confirmed this. 
Therefore, it is clear that not all affected children are being referred to our clinic. 
 
What is certain is that the patients we have seen suffer from severe disease with 
marked pulmonary disease in the main and all have malabsorption and pancreatic 
insufficiency. Sweat chloride levels were all markedly elevated. This elevation is far 
in excess of that seen in malnutrition alone. Thus, our patients present with the 
cardinal features of CF. It does not exclude the fact that less severe disease may also 
exist in this community and as yet has not been recognised locally or seen in our 
clinic. 
 
It is surprising that there have been only two reports of CF occurring in UAE Arab 
patients with neither of those being a UAE Bedouin child. The establishment of a 
medical school in the Al Ain district has drawn doctors who have trained in Western 
countries in which a diagnosis of CF is a common differential. It may be that this 
factor has influenced the referral and diagnosis of these patients. The provision of 
accurate and easily accessible sweat tests is, of course, an essential factor in the 
establishment of the diagnosis and the ease in which it can be made. 
 
The conclusion to be drawn from this study is that CF exists in our national Emirati 
population as a major clinical disease. It is not a rare condition and should be 
 104
considered as part of the differential diagnosis of those with malabsorption with or 
without lung disease in childhood. The extent of less severe disease, the incidence and 
overall prevalence of the condition are all important subjects for continuing study. B
 
Chapter summary 
Twenty children of Bedouin Arab decent from the UAE are described. They all have 
severe clinical manifestations of cystic fibrosis. They form the second largest series of 
Arab children with the disorder that have been reported in the medical literature. 
                                                          
B This section forms the basis of the paper: Cystic Fibrosis in the United Arab Emirates: an Under-
Recognized Condition?6 
 
 105
 References 
 
 
1. Ghubash RO, Lutah MS, Tamira MO. A study on the dawn of modern health 
services in the United Arab Emirates: the British role during the 1930s smallpox 
epidemic. Emirates Medical Journal 1998; 16: 191-8. 
2. Dawson KP, Bakalinova D. Childhood bronchiectasis in a desert location. Middle 
East Paediatrics 1996; 1: 6-8. 
3. Dawson KP, Bakalinova D. Childhood chronic lung disease in the United Arab 
Emirates. Tropical Doctor 1997; 27: 151-153. 
4. Dawson KP, Frossard P. Cystic Fibrosis in the United Arab Emirates: 1. Clinical 
presentation. Emirates Medical Journal 1994; 12: 245-7. 
5. Kaspar P, Moller G, Wahlefeld A. New photometric assay for chymotrypsin in 
stools. Clinical Chemistry 1984; 30: 1753-7. 
6. Dawson KP, Frossard PM. Cystic Fibrosis in the United Arab Emirates: an under-
recognized condition? Tropical Doctor 1995; 25: 110-111. 
 106
Figure 15 
 
A Wadi in the Hajjar Mountains 
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Figure 16 
 
Maha, a three-year-old Emirate girl with 
cystic fibrosis 
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Chapter 8 
 
 
Cystic Fibrosis in the United Arab 
Emirates: Initial Molecular Genetic Studies 
 
 
“Children sweeten labours, but they make misfortunes more bitter” 
 
Of Parents and Children 
Essay 7 
Francis Bacon (1561-1626) 
 
 
The establishment of the respiratory disease clinic and a cystic fibrosis clinic 
subsequently brought about the recognition that CF and other chronic lung diseases 
existed in the UAE childhood population1, 2. We then wished to offer a diagnostic 
service that would incorporate molecular genetic diagnosis. This in turn would permit 
us to investigate the background of CF in the UAE and perhaps later the Gulf Region. 
Part of this strategy involved obtaining funding to establish a molecular genetics 
laboratory in the Faculty of Medicine as the hospitals in the city did neither provide 
nor were willing to provide such facilities. However, with the establishment of the 
clinic, I considered it essential that we did offer a molecular diagnostic service as well 
as clinical advice on patient management. Research funds were obtained to establish 
the laboratory under the aegis of Dr. Philippe Frossard. Thus, we were in the position 
to gather more information about the individual patients and develop a broader view 
of the disease as it presented in the UAE as a whole. Described below are the methods 
used and the results of the first molecular genetic studies on CF in the region. 
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Subjects and Methods 
Subjects 
Mutational analysis was performed on children drawn from 17 families and comprised 
23 children with CF. Fifteen children from ten families were of UAE Bedouin 
descent. They comprised 15 of the 20 children described in Chapter 7. Four families 
were UAE nationals of Baluch origin (five children). Three additional families were 
included (three children) who were not UAE nationals but were Pakistani citizens of 
Baluch origin working in the UAE. 
The ages ranged from one month to eight years. The CF diagnosis in non-Bedouin 
children was based in the same criteria as described in Chapter 7 i.e. elevated sweat 
chloride levels, malabsorption and/or respiratory infection. 
 
Methods 
The children's DNA was extracted from leucocytes isolated from 2-5 mL of venous 
blood collected in EDTA tubes according to standard methods3. 
DNA Analysis 
Detection of ∆F508 was done by denaturing gradient gel electrophoresis (DGGE) 
according to conditions described by Fanen et al.4. 
Denaturing gradient gel electrophoresis strategy. The CFTR gene coding regions 
were amplified in 32 fragments suited to DGGE analysis using PCR primers and 
conditions previously described4, in a multiplex format when possible5. Mutations 
detected by DGGE analysis were identified either by endonuclease restriction analysis 
or direct DNA sequencing6 using a Sequenase DNA sequencing kit and [S35]dATP 
(Amersham International plc). 
 110
Detection of S549R by restriction endonuclease analysis. The mutation S549R 
localised in exon 11 (T→G at nucleotide 1779) alters a Dra III restriction site. Five 
microlitres (500 ng) of exon 11 PCR products, amplified between CF11 and GCCF 11 
without GC-tail4 were digested overnight at 37°C with 6 units of Dra III (Sigma); 
DNA fragments were visualised by 6.5% non-denaturing polyacrylamide gel 
electrophoresis. 
 
 
Results 
In the 15 UAE national patients of Bedouin descent, all CF patients were homozygous 
for the same DGGE mutant pattern in exon 11 whereas their parents were 
heterozygous. This shift in mobility was identified by DNA sequencing as the S549R 
mutation (T to G transversion at nucleotide 1779). This mutation abolishes a Dra III 
restriction site: S549 alleles, on which the Dra II site has been abolished, are detected 
as 189 bp fragments; R549 alleles are evidenced as 107 and 82 bp fragments. All of 
these 15 CF patients were S549 R homozygous (see Figure 17). 
 
In six families out of seven of Baluch ethnicity, CF patients were ∆F508 homozygotes 
(Table 9). In the seventh family of Pakistani Baluch ethnicity, the elder of two sisters, 
aged 8 and 5 years, presented was included. They had presented with milder forms of 
CF, sweat chloride concentrations were in the 50-60 mmol/L range, as opposed to 
100-160 mmol/L in the other patients (i.e those homozygous for ∆F508).  
 
Comments 
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We approached this study with the expectation that the majority of patients would 
carry at least one allele with the mutation ∆F508. It came as a surprise to find that 
none of the UAE Bedouin children in our sample carried such a mutation. Similarly, it 
was an unexpected finding that all but one of the Baluch UAE patients were 
homozygous for the ∆F508 mutation. The remaining Baluch child still presents 
difficulties in defining her mutation even after gene sequencing. The three "control" 
Pakistani patients were similar to the UAE Baluch children, being homozygous for the 
same mutation. 
 
We have identified the main CF-causing mutation in the Bedouin as the S549R 
(T→G) mutation with all the patients examined to date being homozygous for this 
mutation. In the sample of 30 Bedouin alleles examined none carried the ∆F508 
mutation. The ∆F508 has a worldwide frequency of 70% in all mutated CF alleles. 
The lowest community values reported are in the range of 25-30% among Southeast 
Asians and patients from the Indian Subcontinent7, 8, 9. Paradoxically, it was those of 
Indian Subcontinental descent who exhibited this mutation in our series 
 
We have to consider, of course, the limited size of the CF sample analysed and 
whether the patient group studied is representative of the UAE CF population at large. 
However, the absence of the ∆F508 mutation in the 30 alleles examined from Bedouin 
patients is far fewer than the 25% minimum that one could expect. In addition, one 
has to consider the fact that there may be other mutations present that we have not yet 
identified. As mutation frequencies vary among different ethnic groups and 
geographic locations, it does seem important to make an inventory of all the CF 
mutations and their frequencies in the UAE society. It may be that if there are a 
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limited number of mutations, that population screening may be appropriate and 
feasible. 
 
Until very recently, the indigenous population of the UAE was organised into a small 
number of Bedouin tribes that often consisted of individual, although extended, 
families. The UAE society is thus the epitome of an ethnic population that is 
characterised by a rapid expansion a small number of families. The S549R (T→G) 
mutation accounts for 100% of the 30 CF alleles in families of Bedouin descent. It is 
thus tempting thus to speculate that this high rate of one single mutation is the result 
of a founder effect in a common ancestral family.C
 
 
 
 
                                                          
C This work has given rise to two papers: Cystic Fibrosis Mutations in the United Arab Emirates: 2. 
Molecular Genetic Analysis10 and Identification of Cystic Fibrosis Mutations in the United Arab 
Emirates11 
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 Table 9 
 
 
 
Distribution by ethnicity and by ethnic origins of 
the CF patients and their families and the 
number of alleles carrying the two mutations, 
S549R (T→G) and ∆F508. 
 
 
 
     
Ethnic 
Origin 
Number of 
Families 
Number of 
Patients 
Mutation Number of 
CF Alleles 
     
UAE 
Nationals 
Bedouin 
descent 
10 15 S549R 30 of 30 
UAE 
Nationals 
Baluch 
descent 
4 5 ∆F508 8 of 10 
Pakistani 
Baluch 
3 3 ∆F508 6 of 6 
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Figure 17 
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Figure 24 
 
 
Othman: an eleven year old
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Chapter 9 
 
 
The Determination of the Frequency of Two 
Cystic Fibrosis Mutations by Carrier 
Screening 
 
 
 
“If you can look into the seeds of time 
  And say which grain will grow and which will not” 
 
MacBeth 1,3, 58 
William Shakespeare (1564-1616) 
 
 
Clearly the prevalence of CF in the UAE is unknown. Examination of all referred 
patients indicated that two mutations, ∆F508 and S549R (T→G), accounted for 54 out 
of 56 (96%) of CF alleles studied. All patients that we have investigated were 
homozygous for either of the two mutations: 20 CF patients (who were of Bedouin 
origin) were S549R (T→G) homozygotes and seven patients of eight studied (who 
were of Baluch lineage) were ∆F508 homozygotes1. In light of these observations, we 
designed a study aimed at screening CFTR genes of a random sample of the 
indigenous UAE population for asymptomatic S549R (T→G) and ∆F508 carrier 
status. The aim was gain information about the frequency of these genes in the 
population at large. An obvious fundamental difficulty was in obtaining a true random 
sample that would reflect the population as a whole and contained unrelated subjects. 
As discussed earlier, information pertaining to ethnicity and family relationships is 
difficult to obtain for cultural and political reasons. 
 
Methods 
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The sample population for the study comprised 400 unrelated UAE nationals (200 
males and 200 females). These subjects were part of another separate investigation 
into a range of inherited skin disorders. Local Arabic speakers employed for the 
dermatological study documented details of family histories and tribal backgrounds. 
Information so obtained confirmed the lack of close family ties to other members of 
the sample. The sample appeared to be one drawn from the majority of tribes found in 
the UAE. As best one could judge by the data, it represented as good as sample as was 
practical in light of the cultural difficulties. The actual volunteers were recruited from 
general practice attendees at the specific practices nominated for national patients. All 
attendees had trivial medical problems or were simply accompanying persons. Full 
ethical approval had been obtained for this process and there was informed volunteer 
participation. 
 
Detection of ∆F508 was carried out by non-denaturing polyacryamide gel 
electrophoresis (PAGE). PCR reactions were performed on 500ng DNA samples 
using primers and conditions previously described in Chapter 82. Mutation S549R is 
localised to exon 11 (T→G at nucleotide 1779) and alters a Dra III restriction site. 
Detection of the mutation was carried out routinely by Dra III restriction 
endonuclease analysis of exon 11 PCR products, which were generated using 
CGCF113 without a GC-tail as the sense primer and CF113 as the anti-sense primer. 
Five hundred nanograms of PCR products were digested overnight at 37°C with 5U of 
Dra III (New England Biolabs) into a final volume of 20µL. Restriction digests were 
then dried down to 8µL and loaded on 8 cm long, 6.6% non-denaturing 
polyacrylamide gels (Hoefer Scientific Instruments), San Francisco, CA: 
electrophoreses were carried out at 75V for 1.5 hours. Presence of suspected ∆F508 
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and S549R (T→G) mutants alleles was confirmed by sequencing analyses according 
to protocols that have been described in Chapter 8. 
 
Results 
 
Screening of the 800 chromosomes led to the detection of six carriers: four individuals 
were S549R (T→G) heterozygotes and two were ∆F508 heterozygotes (Table 10). 
The estimated frequencies of carriers of each of the two mutations in the population 
are thus: S549R (T→G) 1:100, ∆F508 1:200. Given that ∆F508 and S549R (T→G) 
mutations characterise 96% of CF alleles1, however, the estimated carrier frequency 
of any CF mutation in the population of the UAE is [6 x (100/96)]/ 400 = 1:64. To 
estimate the 95% confidence interval for this number, the formula M - tsM < µ > M 
tsM was applied. (M = sample size, sM estimate of population standard deviation, t = 
t distribution and degrees of freedom). The confidence interval obtained was 6 ±0.5. 
 
We cannot assume that genotype frequencies occur in Hardy-Weinberg proportion4. 
The high rates of consanguinity at 53%, require an adjustment factor (F) to allow for 
this. The correction for consanguinity used is for recessive alleles i.e. aa genotype 
frequency = q2(1-F) + qF. A consanguinity factor of 0.5 (F = 0.022) was used.5 Thus 
the corrected equation is 1/128 x 1/128 (1-0.022) + 1/128 x 0.022. 
The result of the calculation for the combined estimated frequency of individuals 
homozygous for the mutant CF alleles gives a figure of 1:4318. A birth frequency for 
CF is therefore, at least, one in 4,318 births. 
 
Discussion 
 
Within a period of two years, a total of 30 children of UAE nationality were attending 
the CF Clinic. Additional children of various other Arab and non-Arab ethnic groups 
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were also being seen. I inferred previously that we might not be seeing all children 
with the disorder due to under diagnosis and patient management elsewhere. If by 
some chance we were seeing all children with CF, then with a National population of 
750,000 people, the population prevalence would in the order of 1:25,000 (minimum 
de facto prevalence). 
 
It was considered that one could gain a more informed estimate of the potential birth 
frequency of the gene mutations from a random sample of the UAE population. A 
major difficulty, of course, was in obtaining a true population sample. This was in part 
due to the secretive nature of this society and to the fact that "degrees" of citizenship 
occur depending upon one's ancestry. Thus, in general, this type of information is not 
released. I attempted to address this specific problem by the selection of the 
dermatology study group, rather than duplicate the interview methods. 
 
The second difficulty lay in the structure of the society. As alluded to earlier, UAE 
society has evolved by the expansion of a small number of families. Consanguinity 
has reached levels of 53% and is only reducing in the youngest and highly educated 
sector of the society. Family size remains large with an average of seven children per 
family. These factors will reduce the frequency of heterozygotes and increase the 
frequency of homozygotes present. Hence the Hardy-Weinberg law does not apply in 
these circumstances. The consanguinity factor has been applied. The selected 
consanguinity factor has been based upon the work of Al-Awadi et al5 who found that 
the rate of consanguineous mating in Kuwait was 54.3% and the average inbreeding 
coefficient was 0.0219. 
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The estimates rely on small numbers –30 CF patients and 6 asymptomatic carriers in a 
sample size of 400. Clearly one has to remain cautious with their interpretation. 
Furthermore, a population bias is possibly introduced by the organisation of the UAE 
indigenous society into tribes, several members of which still live in remote desert 
areas. In the sample population recruited for this study, we could therefore have 
missed out isolated affected families. The random sample was not analysed for the its 
distribution of Baluch and Bedouin and no information exists as to the degree of inter 
breeding between the groups. Personal observation suggests that this is rare. Hence 
calculations for the individual ethnic groups would not be valid. For these reasons, the 
predicted CF incidence of 1:4318 among Emirati is probably a conservative estimate. 
 
CF until recently has been a fatal and under-recognised condition in the UAE. 
Population prevalence will, therefore be different to birth frequency. In our studies to 
date we have not found a patient with a history of meconium ileus. It could be argued 
that many of the infants might have died from this condition which is usually fatal 
soon after birth if untreated and not recognised. However, the study of 10,000 births at 
the Tawam Hospital, identified only two infants with the condition. Neither of these 
infants were Arab children and both survived.  
 
Although the value of genetic testing is clear, the perception of genetic screening 
varies but there now seems to be general agreement across countries that the 
pendulum has swung towards the side of seeking information on CF carrier status6-8. 
The goals of carrier screening projects are two-fold: 1) to provide informed 
reproductive choices; and 2) to identify couples at risk in order to give them the 
opportunity to reduce the “phenotype load” in affected families8. At this point, 
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introducing a large-scale carrier-screening programme for a disease such as CF 
(despite a high prevalence at birth) is considered premature at best in this rapidly 
developing society. In the UAE, however, genetic testing for CF could certainly be 
offered to adult individuals with a positive family history of CF, to couples planning a 
pregnancy and to couples seeking prenatal care. 
 
From this study it is suggested that the social structure and high consanguinity rates 
have increased the rates of the relatively rare disease, CF. The lethal nature of the 
condition when untreated has to date masked the true situation. It may be expected 
with increased medical vigilance and the eventual advent of screening that the true 
nature and frequency of the condition will be recognised more widely.  
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Table 10 
 
 
Heterozygote frequencies of the two 
common cystic fibrosis mutations in 400 
random, unrelated UAE individuals 
 
 
 
 
 S549R ∆F508 Total 
Number of 
heterozygotes 
4 2 6 
% in the population 1 0.5 1.5 
Frequency in the 
population 
1:100 1:200 1:64 
 
 
 
 124
References 
 
 
1. Frossard PM, Girodon E, Dawson KP, Ghanem N, Plassa F, Lestrigent GG, 
Goossens M, Identification of cystic fibrosis mutations in the United Arab 
Emirates. Human Mutation 1997; 11: 412-3. 
2. Wagner M, Schloesser M, Reiss J. Direct gene diagnosis of cystic fibrosis by 
allele-specific polymerase chain reactions. Molecular Medicine and Biology 1990; 
7: 359-64. 
3. Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B, Plassa F, 
Goossens M, Molecular characterization of cystic fibrosis.16 novel mutations 
identified by analysis of the whole cystic fibrosis conductance transmembrane 
regulator (CFTR) coding regions and splice site junctions. Genomics 1992; 13: 
770.  
4. Hardy Weinberg equation of population genetics. 
Http://www.people.virginia.edu/~rjh9u/hwequa.htlm. 
5. Al-Awadi SA, Moussa MA, Naguib KK, Farag TI, Teebi AS, el-Khalifa M, el-
Dossary L. Consanguinity among the Kuwaiti population. Clinical Genetics 1985; 
27: 438-6. 
6. Scriver CR, Fujiwara TM. Cystic fibrosis genotypes and views on screening are 
both heterogeneous and population related. American Journal of Human Genetics 
1992; 51: 943-50. 
7. National Institute of Health. Genetic screening for cystic fibrosis. NIH Consensus 
Statement 154 April 14-16. 1997. 
8. Schmidtke J. A commentary on the NIH Consensus Development Statement 
“Genetic Testing for Cystic Fibrosis”. Community Genetics 1998; 1: 53. 
 125
Chapter 10 
 
 
The S549R (T→G) Cystic Fibrosis Mutation 
 
 
 
 
“The young disease, that must subdue at length, 
 Grows with his growth, and strengthens with his strength” 
 
An Essay on Man 1,135 
Alexander Pope (1688-1744) 
 
 
 
CF in UAE Bedouin children is associated with the mutation S549R (T→G) [S549R] 
in the children so far identified. This mutation has been rarely reported (see summary 
at the end of this chapter) and hence several questions needed to be addressed. Could 
we confirm that there was a severe clinical phenotype associated with this genotype? 
Was it possible to compare the clinical phenotype produced in patients who are 
homozygous for S549R with those homozygous for ∆F508 mutations that are resident 
in the UAE. Is there a practical value in this society in having a rapid diagnostic 
service for CF mutations? 
 
This chapter reports several studies aimed at answering these questions or providing 
at least some new information. 
 
 
Is the clinical severity of mutation S549R (T→G) extreme?  
 
 
Having acquired the knowledge that thirty of our patients had CF as a result of S549R 
mutations, fifteen of the earlier patients have been reviewed specifically to address the 
severity of their clinical disease.  
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Subjects and methods 
Patients: The study group consisted of 15 CF patients (9 girls and 6 boys) who were 
all UAE nationals of Bedouin origin. They were drawn from thirty patients diagnosed 
as having CF due to the mutation S549R. Ten of the patients are from the group 
briefly described in Chapter 9. All patients were referred directly to me at the Cystic 
Fibrosis Clinic of Tawam Hospital (Al Ain, Abu Dhabi Emirate, United Arab 
Emirates) from 1993. The Research Ethics Committee of the Faculty of Medicine and 
Health Sciences, UAE University, Al Ain, UAE approved the protocol for this CF 
programme. 
 
Initial clinical investigations: 
General outcome variables that were evaluated in this investigation included current 
age, age at diagnosis, sweat chloride values (measured by quantitative pilocarpine 
iontophoresis), height, weight and weight for height percentiles (from most recent 
clinic visits), and Shwachman-Kulczycki scores1 (Table 11). All results are presented 
as means and standard deviations as determined for the 15 patients.  
. 
The presence or absence of the following presenting clinical problems was recorded 
(Table 11): meconium ileus, pulmonary problems, failure to thrive, diarrhoea. The 
presence of pancreatic insufficiency was determined on the basis of requirement for 
pancreatic enzyme supplementation to control steatorrhea and the measurement of 
stool chymotrypsin activity. Associated complications included nasal polyps, sinusitis, 
pancreatitis, diabetes mellitus, and rectal prolapse (Table 11). 
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Respiratory bacterial infections (Pseudomonas aeruginosa and Staphylococcus 
aureus) were determined as the first positive culture on record, and cultures of 
tracheal aspirates were performed in the case of children who were too young to 
provide sputum or cough swab samples (Table 11). 
 
Due to the young age of the subjects, regular pulmonary function tests on all subjects 
could not be performed. Radiological analyses as appropriate were carried out to 
evaluate both the extent and the severity of lung disease. 
 
Treatment and management 
All patients were commenced on pancreatic enzymes, dietary and nutritional 
supplements including multivitamins from the time of diagnosis. Selected individuals 
had nasogastric night feeds and total parentral nutrition. No patient had a gastrostomy 
feeding port. This was on the basis of a cultural bias against such devices. Aggressive 
antibiotic therapy as guided by sputum culture, cough swabs or tracheal aspirates was 
practised. Nebulised hypertonic saline or pulmozyme was used for those with 
extensive lung disease on an individual basis. Regular inhalation of tobramycin via a 
nebuliser was prescribed for those with pseudomonas colonisation. Inhaled steroids 
and bronchodilator therapy was prescribed again on an individual basis. 
 
Results 
 
The clinical presentation and details of the 15 CF children (6 boys and 9 girls) is 
given as pooled data in Table 11. Mean current age was 5.4±3.5 years, mean age at 
diagnosis was 1.0±1.1 year. Sweat chloride concentrations were 120±21 mmol/L 
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(range: 105-155 mmol/L), and Shwachman scores (45.5±7.0) were in keeping with an 
extremely severe, overall clinical manifestation. 
 
No child had presented with meconium ileus at birth, but all were pancreatic 
insufficient (PI) and had severe pulmonary disease. None of the 15 CF patients had 
associated complications (Table 11). Pseudomonas and Staphylococcus colonisation 
were frequently observed (9 and 7 cases out of 15, respectively). 
 
Discussion 
 
The clinical data does support the concept that S549R is a very severe mutational 
allele. First of all, the age at diagnosis was low (1.0±1.1 year, see Table 11) 
supporting an early and severe presentation of clinical effects. Sweat chloride 
concentrations associated with S549R homozygosity were high, even at very young 
ages (mean sweat chloride levels in the group of 15 patients were 120±21 mmol/L). 
All 15 patients exhibited the PI phenotype. Chronic infections with Pseudomonas 
aeruginosa and Staphylococcus aureus were present in 9 and 7 patients, respectively, 
and were found unusually at very young ages. Overall Shwachman-Kulczycki scores, 
as well as height and weight percentiles, were poor (see Table 11) and support a 
severe clinical phenotype. 
 
A remarkable feature of the clinical presentation associated with S549R in the UAE is 
that none of the 15 homozygous patients had presented with meconium ileus at birth. 
This contrasts with mutation ∆F508, which is frequently associated with meconium 
ileus2. Furthermore, ∆F508 subjects who present with meconium ileus are more likely 
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to be colonised earlier with Pseudomonas3. In R549 homozygotes, the rate of serious 
chronic infections (including Pseudomonas) is high and severe pathogenic 
colonisation occurs early in life. Early colonisation by Pseudomonas has also been 
reported in CF patients from Saudi Arabia4, which tends to indicate that genetic as 
well as non-genetic factors play an aggravating role in the course of CF in this part of 
the world. 
 
It is also interesting to note that, besides meconium ileus, none of the 15 patients has 
showed evidence of classically associated complications such as rectal prolapse or 
nasal polyps (Table 11). All 15 patients, however, have had severe pulmonary 
complications. Even though we were unable to perform pulmonary function tests on 
the patients in this study, the severity of radiological findings (see below) on 12 of 
these patients lead us to conclude that the pulmonary phenotype was extremely severe 
in all 15 R549 homozygous patients. 
 
Although there is usually good correlation between CFTR genotype and pancreatic 
function status, genotypes have failed to predict pulmonary severity so that the patho-
physiology of lung complications remains elusive5-12. Our results also point to the fact 
that the pulmonary phenotype associated with R549 mutations is indeed fairly 
heterogeneous, although it indicates a marked overall severity. Despite this severity 
the oldest surviving patient, however, who has complied well with therapeutic 
interventions, is now 12 years old and may well have a reasonable prognosis. 
 
In conclusion, genotype-phenotype analysis in CF patients from the UAE shows that 
the R549 allele is associated with an extremely severe clinical presentation. Detection 
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of the S549R mutation is thus imperative in these CF children, as aggressive treatment 
and management modalities should be instigated as soon as possible in order to 
increase patient chances of survival. 
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Table 11 
 
 
Clinical description of CF patients with CFTR 
mutation S549R (T→G). 
 
 
Variable R549/R549 
 
Patients (n) 15  (6M, 9F) 
Mean current age (years) 5.4 ±  3.5 
Range 1 - 12 
Mean age at diagnosis (years) 1.0 ±  1.1 
Range 1.0 - 3 
Sweat chloride mmol/L 120.0 ±  21.0 
Shwachman score 45 ±  7.0 
Height percentile <3rd  - 10th 
Weight percentile <3rd  - 5th 
Presentation (n)  
  Meconium ileus 0 
  Pulmonary 14 
  Failure to thrive 13 
  Diarrhoea 10 
Absent chymotrypsin activity in 
stool 
7 
Pancreatic insufficiency 15 
Associated complications* 0 
Pseudomonas colonisation 9 
Staphylococcus colonisation 7 
  
 
 
Values are mean ± SD: M Male, F Female 
*Associated complications: nasal polyps, sinusitis, pancreatitis, diabetes mellitus, 
rectal prolapse. 
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To obtain further information about the pulmonary status of the children described 
above an analysis of their radiological findings over time was carried out. The patients 
were drawn from the group described above, but only those with full radiological 
assessment were included. 
 
Patients and Methods 
 
Patients 
The study group consisted of 12 CF patients who were all UAE nationals of Bedouin 
origin.  
The CF group included eight girls and four boys. The mean age of the group was 4.1 
± 3.3 years, and the age at diagnosis had been 10 ± 9 months. All 12 patients were 
pancreatic insufficient (PI) and the mean sweat chloride value (as demonstrated by 
quantitative pilocarpine iontophoresis) was 119 ± 17mmol/L. None of these patients 
had presented with meconium ileus at birth, but they all had experienced pulmonary 
complications at the time of diagnosis. 
 
Clinical investigations 
 
Detailed radiological analyses were carried out in the 12 patients by a single observer 
in order to evaluate both the severity and the extent of the lung disease. Thus, all 12 
children had a series of chest radiographs (PA and lateral). Radiological features of 
CF were recorded from the start of the disease until the last chest radiograph, which 
enabled comparisons and facilitated the evaluation of the progression shown on 
sequential chest films. Ultrasound examinations of the abdomen were carried out in 
four children and one child had high-resolution computerised radiography (HRCT) of 
the lungs. 
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 Results 
 
To evaluate the lung pathology on chest radiographs, the 12 CF children were placed 
into two groups – below and above two years of age. 
 
In the group of six children who were two years old or younger, a picture of 
hyperinflation was dominant. Due to bronchoconstriction in peripheral airways, the 
lungs appeared extremely hyperinflated, with associated depression of the diaphragm 
and sternal bowing. Five children had bronchial line shadows that were due to 
thickening of the peribronchial interstitial tissues resulting from inflammation caused 
by proven respiratory syncytial virus infections. This triggered very early, severe and 
persistent obstruction in the youngest patients. 
 
Ring shadows representing bronchiolectatic cavities were seen in three of the infants 
below one year of age. These were mainly localised in the superior and posterior 
segments of the lower lobes. One six month–old baby presented with persistent 
collapse of a segment of the middle lobe, which was due to mucous plugs obstruction. 
One other patient of this younger group presented with radiological features of 
pneumonia. 
 
The six CF patients who were older than two years presented with mottled and ring 
shadows of bronchiectatic dilatation of the airways. Mottled shadows were round 
shadows with ill-defined edges caused by abscesses with a lobular distribution. In one 
patient, these were persistently found on all chest radiographs during follow-up. 
Lobular infections were diffusely distributed throughout all lobes. 
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 Ring shadows of dilated bronchioles with thick walls were present in all five patients 
who were five years or older. These were mainly distributed in the upper lobes and 
posterior segments of the lower lobes. Ring shadows were the dominant component of 
the lung pathology in these children and their severity gradually increased with age. 
 
One five-year old patient had a very prominent interstitium with noticeable 
peribronchial and perivascular bundle branches and reticular shadows of lung fibrosis. 
Lung fibrosis was diagnosed on HRCT in one 9-year old patient. This was the only 
child followed by CT in the overall group of patients. A mosaic perfusion pattern and 
air trapping with peribronchial thickening was the dominant radiological finding. Four 
children of this group showed tracheomegaly that was most probably due to chronic 
recurrent inflammation.  This led to enlargement of the major airways and structural 
abnormalities in the tracheal walls, which became flaccid. 
 
There was no evidence of honeycombing and bullous change in any of the 12 CF 
patients who were included in this analysis. However, inflammatory mucosal oedema 
and accumulation of mucopurulent secretions were the main reason for the 
hyperinflation that was observed in children of all age groups. 
 
Two patients had enlargement of the liver with hyperechogenic parenchyma 
suggestive of fatty infiltration. One child showed a hyperechogenic pancreas due to 
fatty infiltration. One other patient had gross hepatomegaly and fatty infiltration. 
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Changes in cardiac configuration occurred in all patients with CF in early infancy. 
Due to severe obstruction, which contributed to increased lung volume, the heart 
shape became elongated. Early features of cor pulmonale were seen in three children. 
Enlargement of the main pulmonary artery was seen in four children at age 3-7 years. 
Enlargements of main pulmonary artery shadows in the hila occurred in two children 
in the early stages. These two patients later developed heart failure. 
 
Discussion 
 
The information that we obtained from chest radiographs in the cohort of 12 CF 
patients revealed a high degree of complexity of radiological findings which required 
subsequent detailed analysis. Diversity of pulmonary changes and associated 
radiological expressions showed remarkably severe hyperinflation in early infancy in 
conjunction with inflammation of the interstitium. The main findings consisted of 
depressed diaphragms and sternal bowing with reduction of vascular shadows on the 
periphery. These infants also presented with early signs of liver involvement, as 
assessed by ultrasound examination. 
 
In the older age group (i.e. above two years), signs of central airways involvement 
occurred in association with early signs of pulmonary hypertension. This indicates 
that aggressive patient management is required in these children. 
 
These combined findings clearly indicate that the phenotypic expression of lung 
disease due to CFTR mutation S549R (T→G) is extremely severe and that there is a 
rapid decline in the pulmonary status of these patients. In this respect, the pulmonary 
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phenotype expression of mutation S549R (T→G) appears to be at least as severe as 
that of mutation ∆F508. 
 
 
 
 
 
Summary 
In answer to the question regarding the degree of clinical severity associated with the 
S549R mutation, the overall clinical presentation of CF in these R549 homozygous 
patients is extreme. Furthermore, Pseudomonas aeruginosa and Staphylococcus 
aureus colonisation was frequently observed (in, respectively, eight and six cases) and 
occurred at an unusually early age (at least four patients had been recorded as having 
presented with Pseudomonas or Staphylococcal infections by three months of age).D
 
                                                          
D The above findings gave rise to two papers: Genotype-phenotype correlations in cystic fibrosis13 and 
Radiological analysis of children with cystic fibrosis who are homozygous for the CFTR mutation 
S549R14 
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Is it possible in the UAE to compare disease severity associated with Cystic 
Fibrosis mutations ∆F08 and S549R (T→G)? 
 
 
To date the children with the S549R mutation all have had severe disease. Indeed, it 
appeared to me to be as severe as I had seen before elsewhere. The clinical phenotype 
associated with the ∆F508 mutation is usually regarded as the "gold standard" for 
comparison. Clearly, as outlined in the literature review other mutations around exons 
10 and 11 produce severe disease also. The purpose of this section is an attempt to 
compare the disease severity associated with each of these two mutations as they 
present in the UAE. In our situation, the environmental factors and health care access 
are uniform and controlled and the patients are homozygous for their respective 
mutations. While there may be ethnic differences between groups, these are not 
apparent in day to day living and there are no obvious socio-economic differences. 
Indeed, those of Baluch and Iranian descent are more than likely to be represented in 
the professional groups. 
 
Methods 
 
Subjects 
The study subjects consisted of two groups of 5 children who were age- and sex-
matched and were homozygous for the mutation S549R (T→G) or ∆F508 (Table 12). 
There were two males and three females in each group. I also compare the group of 5 
CF, ∆F508 homozygote patients with a non-matched group of 15 CF children who are 
S549R (T→G) homozygotes. This latter group, that I have described earlier, includes 
the 5 patients constituting the matched S549R (T→G) group. 
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The overall number of CF patients in this study may appear as relatively small. I have 
shown previously, however, that these subjects constitute the pool of most of the CF 
patients found in the UAE, and the overall pool of 20 patients investigated here has 
been actively recruited over the past few years. 
 
All children, as UAE citizens, have free access to hospital care and the costs of their 
inpatient care, drugs and investigations are met by the State. Management plans were 
instigated and supervised by me, but were individualised. 
 
Clinical investigation 
 
Data was collected from the matched children with regard to age, age at diagnosis, 
current height and weight percentiles. A Shwachman score was calculated for each 
child1. Data was expressed as means for the separate CF mutation groups with one 
standard deviation. Information was collected also with regard to the following: 
history of meconium ileus, pulmonary infection, evidence of pancreatic insufficiency 
(determined on the basis of enzyme replacement and /or chymotryptic activity in the 
stool), associated problems viz. nasal polyps, sinusitis, pancreatitis, diabetes mellitus 
or rectal prolapse. The presence of respiratory tract colonisation was noted and the 
presence of specific organisms was based upon positive sputum cultures or tracheal 
aspirate results. 
 
Results 
 
The comparative pooled data for both groups of children are listed in Table 12. 
Included for comparison is the findings from 15 children with mutation S549R 
(T→G) previously described. In the matched groups the main difference is the earlier 
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diagnosis in the ∆F508 group, while Shwachman scores show no difference and sweat 
electrolyte levels are marginally higher in the S549R (T→G) group. The mean sweat 
chloride levels were higher in both the matched and unmatched S549R (T→G) 
groups. This did not reach statistical significance (p = 0.34). Similarly, the age at 
diagnosis for the ∆F508 patients was earlier than both other groups, but again did not 
reach a significant level (p = 0.57). 
 
Discussion 
 
These findings support the view that the S549R (T→G) CF mutation is associated 
with a clinically severe form of the disease. Further, the results are in keeping with 
our further contention that the clinical disease associated with the mutation in the 
homozygous state is as severe as that produced by the ∆F508 mutation. The major 
difference found between the age- and sex-matched patients was that the diagnosis 
was established earlier in the group of ∆F508 homozygotes. However, despite this, 
there was no difference in the Shwachman Scores between groups. One of the unique 
features of this study is that all the patients are homozygous for their particular 
mutation, live in the same harsh climatic and physical environment and have free 
access to health care. I have included another group of patients with S549R (T→G) in 
Table 12 whose details have been given. The clinical details from this larger group 
suggest that our age- and sex-matched sample do reflect the general pattern of disease 
found in our society resulting from the mutation. However, it is of interest to note that 
in general the diagnosis was made earlier than in the matched group and was nearer to 
that of the group of ∆F508 homozygotes. 
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The severity of CF mutations has usually been based upon whether there is pancreatic 
sufficiency or not. ∆F508 is regarded as a severe mutation conferring marked 
pancreatic insufficiency and the presence of meconium ileus in 10-15% of the 
affected neonates14. In addition, the mutation is usually associated with lung disease. 
This mutation remains the common severe mutation wordwide and results in major 
CFTR chloride channel disruption and produces little channel activity. It has been 
labelled as a class II mutation (defective protein processing) which results in the 
failure of the protein to reach the epithelial membrane8. Further, the R549 mutant has 
also been shown to fail to yield the fully glycosylated form of the protein. This in turn 
leads to its failure to reach its correct cellular location (as occurs with ∆F508). The 
S549R (T→G) mutation is thus also a class II mutation15, 16 Hence our clinical 
findings are in keeping with the molecular changes.  
 
The patients we have described match the classical homozygote pattern for ∆F508, 
chronic obstruction and infection of the respiratory tract, pancreatic insufficiency and 
elevated levels of sweat electrolytes10. However, we have not seen a patient, 
homozygous for either of the studied mutations, in the UAE who presented with 
meconium ileus. As the patients studied here were all pancreatic insufficient, and if 
we take into account the range of 10-15%38, we would have expected to observe two 
to three neonates with meconium ileus in the overall cohort of 20 subjects. Whether 
the small sample size accounts for the lack of significance or whether additional 
factors play a role in the absence of meconium ileus among UAE patients remain to 
be elucidated. Similarly, the higher sweat chloride levels in the S549R (T→G) 
patients may reach significance if and when additional ∆F508 patients are found. The 
apparent, but statistically insignificant, earlier diagnosis age of ∆F508 patients is 
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unlikely to be to a referral bias, but may reflect a cultural difference and hence 
different social expectations. My experience of this group suggests that it is unlikely. 
 
I conclude from this study that S549R (T→G) homozygote patients have severe 
clinical disease and that this disease severity equates with the clinical severity of 
∆F508 homozygote patients. These clinical findings are in keeping with the known 
molecular modifications affecting the CFTR gene.  
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Figure 27 
Clubbing
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 Table 12 
 
 
Clinical data associated with CFTR 
mutations S549R (T→G) and ∆F508 
 
 
 
Variable Matched 
∆F508/∆F508 
(n = 5) 
Matched 
S549R/S549R 
(n = 5) 
Non-matched 
S549R/S549R 
(n = 15) 
    
Current age range 
(months) 
36-120 36-120 1-144 
Mean age 
(months) at 
diagnosis ± SD* 
6.8 ± 4.2 
(range 2-12) 
22.0 ± 25.6 
(range 1-60) 
12.0 ±13.0 
(range 2-36) 
Mean sweat 
chloride level 
(mmol/L) ±SD** 
97.8 ± 19.1 113.0 ± 23.3 120.0 ± 21.0 
Shwachman score 
± S.D. 
45.0 ± 5.7 45.4 ± 5.1 45.5 ± 7.0 
Pancreatic 
insufficiency 
4/5 5/5 15/15 
Pseudomonas 
colonisation 
4/5 2/5 9/15 
Meconium ileus 0/5 0/5 0/15 
    
    
 
• p = 0.57 (ns) 
• p = 0.34 (ns) 
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Is there a practical value in having a rapid diagnostic service for CF mutations? 
 
 
To support the argument that it is of value to have this service available, I present 
below two clinical examples. The knowledge of the CFTR mutation aided in the 
diagnosis of one child and was helpful in the management in another. Both examples 
formed case reports which were published in the Gulf Region medical journals. The 
purpose of this was to draw attention to the condition locally and to stress that CF 
should be considered in the differential diagnosis of ill Arab children. Both patients 
were referred to me for diagnosis and the referring paediatricians were included as co-
authors. The reports are presented below in an abridged version of the originals. 
 
 
 
Illustrative Case Reports 
 
Post-mortem confirmation of a rare cystic fibrosis mutation18 
 
AK, a five-month-old infant, was the first child of healthy UAE nationals who were 
first cousins. His birth weight was 3.2 kg. The pregnancy, delivery and neonatal 
period were normal. 
 
He was first admitted to hospital at the age of four months because of failure to thrive 
and diarrhoea. He was anaemic and wasted (weight 3.4 kg.) with hepatosplenomegaly, 
hypoalbuminaemia and a prolonged blood coagulation time. CF was suspected but 
sweat tests were unsuccessful because of an inadequate weight of sweat. Before repeat 
tests could be performed the child was removed from hospital against medical advice. 
 
At aged five months he was readmitted in extremis, shocked, dehydrated, hypoxic and 
jaundiced. Chest radiology revealed extensive atelectasis and widespread opacities. 
He was intubated and ventilated. Pseudomonas aeruginosa was grown from the 
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tracheal aspirate and was shown to be sensitive to amikacin and aztreonam. Despite 
aggressive antibiotic therapy, ventilation and other supportive therapy, there was 
progressive extension of the pneumonia. He died from hypoxia, despite maximal 
ventilatory settings. 
 
Prior to death, blood had been taken for numerous investigations, including DNA 
analysis. Permission to perform a post-mortem examination was withheld. DNA 
analysis revealed a homozygous mutation S549R on exon 11. 
 
Discussion 
 
An infant of UAE nationality and Bedouin origin is described in whom there was a 
very strong suspicion of cystic fibrosis. Parental consanguinity, the patient’s 
diarrhoea, severe failure to thrive and Pseudomonas pneumonia are all strong pointers 
to this diagnosis19. CF is generally considered a rare disease in Arab countries. We 
have recently drawn attention to the fact that in the UAE it appears more common 
than previously considered and that it presents with serious disease13. Associated 
molecular genetic studies found a mutation in close proximity to the ATP-binding 
domains in patients of Bedouin origin20. All these patients have been shown to be 
homozygous for an S549R mutation due to a T→G transversion at nucleotide position 
177020. 
 
The prior knowledge of CF mutations in the population permitted rapid analysis of the 
DNA sample obtained from our patient. This confirmed our clinical diagnosis that the 
patient was homozygous for the S549R mutation and therefore had cystic fibrosis. 
Our patient was the first child of the family and this confirmation of the diagnosis 
made genetic counselling possible. The mutation described is rare, except in the UAE 
where, along with ∆F508 mutation it accounts for over 90% of cases of CF. Prior 
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knowledge of the frequency of this mutation in this specific population thus permitted 
us to establish a definite diagnosis after the death of the child. 
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Pseudo-Bartter’s Syndrome in an Omani infant21 
 
A metabolic alkalosis associated with low serum electrolytes is an uncommon finding 
in infancy and is usually associated with pyloric stenosis, chloride-loosing 
nephropathy or Bartter’s Syndrome22. 
 
Herewith presented are details of an Omani child who developed alkalosis and 
electrolyte disturbance. She had an unusual set of circumstances that produced a 
pseudo-Bartter’s syndrome. 
 
Case Report: 
 
A four-month-old Omani female was admitted to Al Ain Hospital, Al Ain, United 
Arab Emirates with a history of failure to thrive and diarrhoea. She was one of nine 
children (five males and four females) of parents who were first cousins. All the 
siblings were apparently well and the patient was born after a normal pregnancy and 
delivery. 
 
On admission she was wasted and miserable, weighing 2.06 kg. (birth weight 2.4 kg.). 
Her blood pressure at that time was 70/50 mm Hg. Laboratory findings are as follows: 
Serum Na =118 mmol/L, potassium = 2.42 mmol/L, chloride = 70mmol/L, CO2 = 
35.7, base excess – 24.2, serum osmolality = 270 mOsm/kg., urine osmolality = 72 
mOsm/kg., sweat chloride = 35 mmol/L. 
 
Initial treatment was by oral electrolyte solution with added potassium, which resulted 
in a rapid restoration of normal electrolyte levels. However, she failed to gain weight 
and developed an irritating cough and persistent fever. A chest radiograph was in 
keeping with the clinical finding of a bronchopneumonia with marked changes in the 
right lung. 
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Further investigations revealed the absence of urinary sodium loss over 24 hours, 
normal plasma renin and aldosterone levels. The plasma electrolytes remained normal 
without extra potassium while she remained in hospital. The pneumonia was treated 
with antibiotics and, following resolution, further sweat tests were performed. Sweat 
chloride levels in excess of 70 mmol/L were detected. Stool chymotryptic activity was 
1 U/g (normal > 6 U/g. Examination of 7 exon 11 of the CFTR gene localised on 
chromosome 7 revealed a homozygous mutation S549R. The patient was started on a 
regimen that included pancreatic enzymes, vitamin supplements and supplemental 
feeding, after which a 1.6 Kg. weight gain occurred within 14 days. A rapid decrease 
in stool frequency and improved consistency was noted thereafter. On family 
screening, the parents and four siblings were found to be carriers of the S549R CF 
mutation. 
 
Discussion 
 
On admission our patient was given a provisional diagnosis of Bartter’s syndrome. 
This was based on the fact that she had “normal” sweat electrolyte levels, a metabolic 
alkalosis, low plasma electrolytes and normal blood pressure. However, the finding of 
normal plasma renin and angiotensin and the absence of urinary salt wasting refuted 
that diagnosis. After restoration of normal serum electrolyte balance and removal of 
supplements, repeat sweat tests confirmed elevated sweat chloride levels, all in excess 
of 70 mmol/L. It was of interest that despite an adequate weight of sweat, the initial 
sweat test result was within the normal laboratory range. Paradoxically it is known 
that sweat electrolytes can be elevated in malabsorption19. I presume that the false 
sweat test originally was as a result of the profound electrolyte disturbance that the 
child was experiencing. The diagnosis of cystic fibrosis was, however, confirmed 
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beyond doubt by the demonstration of the CF gene mutation S549R. We have 
previously reported this mutation as the main CF-causing mutation in the United Arab 
Emirates population20 and have indicated that the disease caused by it is severe and 
we suspect that the disorder is underdiagnosed23. 
 
The association of pseudo-Bartter’s syndrome and CF has been described before in a 
small number of children from North America24 and the United Kingdom22. Cystic 
fibrosis has been regarded as a rare disease in the Arab and Al-Mabairreek and 
Abdullah described patients in Saudi Arabia with findings consistent with pseudo-
Bartter’s syndrome in many of the twelve children they had seen with CF25. Their 
patients had disturbed electrolyte balance associated with vomiting and failure to 
thrive. 
 
We believe our patient had experienced marked electrolyte loss due to high 
environmental temperatures, aggravated by intercurrent illness and diarrhoea as has 
been described before24. She had a low salt intake and an inadequate solute feed. This 
patient is the first Omani patient to have a defined genetic mutation demonstrated in 
cystic fibrosis. She also typified the problems resulting from the disease and 
exacerbated by high environmental temperatures reaching 45ºC. Her illness should 
alert paediatricians in the Arab world to the possibility of cystic fibrosis in patients 
with a metabolic alkalosis and electrolyte depletion. 
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Brief overview of the S549R (T→G) Cystic Fibrosis Gene Mutation 
 
Cystic fibrosis (CF) is due to variations in DNA which result in modifications in the 
sequence, structure, function and/or expression of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene situated on chromosome 726. Over 1000 CF-
causing mutations have been identified worldwide in the CFTR gene27. While the 
∆F508 mutation accounts for over 60% of these alterations there are a number of 
important mutations being recognised among differing ethnic groups26, 27. Among 
these are the several mutations that have been described in exon 11 of the CFTR. The 
mutation designated S549R (T→G) is a missense mutation occurring at nucleotide 
1779 that is the result of a G (guanine) to T (thymine) transversion. The consequence 
of this mutation, in codon 549, is the replacement of a serine by an arginine in the first 
nucleotide binding domain of the CFTR. Serine is a highly conserved amino acid in 
this important binding domain and its replacement by an arginine residue is expected 
to result in a severe chloride dysfunction and hence severe clinical disease28. S549R is 
defined as a Class II mutation28-32. These are associated with defective protein 
processing. The abnormally processed protein fails to progress through the 
biosynthetic pathway and is degraded. The protein is thus either missing or present in 
reduced amounts in the apical membrane. It is thought that the mutation prevents the 
protein from being properly post- translationally glycosylated. This results in incorrect 
folding, so that the protein is recognised as abnormal and degraded28-32. These events 
appear to be similar to those seen with the ∆F508 mutation in that the misfolded 
protein is trapped in the endoplasmic reticulum prior to its degradation31, 32 E. 
 
                                                          
E This overview gave rise to the paper: The S549R (T→G) Cystic Fibrosis Mutation39 
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The existence of the mutation S549R (T→G), was first reported to the Cystic Fibrosis 
Genetic Analysis Consortium on the 9th of February 1990 by Kerem and Tsui33. The 
individual who carried the CF chromosome was a non-Ashkenazi Jewish patient from 
Morocco who also carried the ∆F508 mutation on the other allele28. Further reference 
to this and one other Moroccan patient was made by Kerem et al.29 who studied cystic 
fibrosis mutations in Jewish communities.  It was reported that CF mutations vary 
within each Jewish ethnic group, each one having its own repertoire of mutations. 
S549R was found only in these two patients from Morocco and it thus accounted for 
6% of the identified Jewish CF patients from that country. 
 
There have been four separate mutations described in codon 549, viz. S549R (A→C), 
S549I, S549R (T→G), and S549N33. A study of 27,177 CF chromosomes from 29 
European and 3 North African countries showed that of the 272 mutations examined, 
S549R occurred on 12 occasions (0.04%) and the S549N on 16 occasions (0.059%). 
Interestingly, despite its general rarity, the S549R mutation accounted for 2.6% of all 
mutations in Algeria8. However, a recent detailed study of 10 Algerian CF families 
revealed no patients with a mutation on exon 1128.  
 
Another important report in the literature regarding the S549R mutation is from Saudi 
Arabia. Banjar et al.36, 37 described a single individual who was homozygous for the 
mutation. The patient was a Saudi native who came from the Eastern Province of 
Saudi Arabia. The affected individual had pancreatic sufficiency and mild chest 
disease. However, El-Harith et al13 investigated 15 Arab children from 12 families 
who had CF. No examples of S549R were detected and it is of significance that the 
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families studied were all from the Eastern Region from where the one previous Saudi 
patient with S549R had been identified. 
 
The data from Eastern Arabia points to S549R (T→G) being a mutation causing 
severe clinical disease and probably as severe as found in CF. The founding mutation 
may have originated in Arabia. However, there is considerable ethnic variation 
between the UAE and Oman, and there is little evidence of the mutation in Bedouin 
Saudis. The reports of sporadic alleles from Israel, North Africa and France confuse 
the issue further. Current evidence suggests the origins lie in Bedouin of Eastern 
Arabia. 
 
Study of what appeared at first to be a rare or private mutation is contributing to our 
understanding of genotype-phenotype correlation. To date the distribution of the 
mutation does not fit patterns of historical population migration such as that 
associated with the ∆F508 mutation28 but it is found mainly in the Bedouin Arab 
people of Oman and the UAE. Disease severity in the homozygous patient appears to 
be very severe. It can be postulated that this severity, in itself, probably accounts for 
the early demise of those with the disease in the early times. With the introduction of 
the medical services in the Gulf Region recognition has occurred of the importance of 
this mutation in the causation of CF in the region.  
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Chapter summary 
I have presented data in this chapter to support my contention that CF due to mutation 
S549R (T→G) results in severe clinical disease. My prior experience with severe CF 
had been with children having the mutation ∆F508. I felt that it would, therefore be 
important to establish a factual basis to my feeling that the clinical disease produced 
by S549R (T→G) mutation was more severe than that produced by ∆F508. I have 
accumulated what evidence I could gather to support this hypothesis. In order to 
control such factors as health care standards, climate, diet and culture I should have 
acquired a larger matched group of children with CF due to ∆F508. However, the 
sex/age matched patients presented are the largest group to be identified in the UAE. 
Thus, I do not have strong evidence to support my claim that the S549R mutation 
produces a more severe clinical disease. There is sufficient evidence to state that the 
mutation creates a clinical disease, which is at least equal in severity to that of ∆F508. 
 
The clinical cases are presented to reinforce the practical use of mutational knowledge 
in the clinical setting. The harsh climate of the region does cause severe salt depletion 
and dehydration and infants with CF are particularly vulnerable. The true cause of 
their dehydration can be missed easily. The finding of an Omani child, later shown to 
have CF, from the neighbouring town of Al-Buraimi, stimulated the idea of looking 
further at the clinical and genetic pattern of CF in the neighbouring country of Oman. 
Information about these investigations is presented in a later chapter. 
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Finally, the rarity of reports about the S549R mutation prompted a summary of the 
known facts. To reduce repetition, the overview has been markedly abridged and the 
remaining information presented in the next chapter. 
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 Chapter 11 
 
 
Does the Cystic Fibrosis Mutation S549R 
(T→G) Always Produce Severe Clinical 
Disease? 
 
“Since ‘tis Nature’s law to change, 
Constancy alone is strange” 
 
Works 
A dialogue between Strephon and Daphne, l 1 
John Wilmot 
Earl of Rochester (1647-1680) 
 
 
The information that has been presented has supported the view that all patients who 
carry the CF mutation S549R (T→G) have severe clinical disease. However, to date I 
have reported only on patients who are homozygous for the mutation. With increasing 
access to patients throughout the UAE and from the ever-expanding patient pool, we 
encountered one CF patient who had mild clinical disease. At this time he proved to 
be a unique patient and family in the UAE. Hence, the clinical details of this older 
child are presented in this chapter (Section I) along with the relevant molecular 
genetic findings. These findings indicated that in the heterozygote, severe disease 
does not always ensue. 
 
A close relationship had been established, by this time, with the Paris-based group led 
by Professor Emmanuelle Girodon. They had acted as a peer review group for us and 
had provided additional and separate laboratory confirmation of our results. Following 
the publication of a joint paper with the group on the clinical severity and mutation 
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identification of CF in the UAE, we were approached by another French molecular 
genetic group. Professor Mireille Claustres from Montpellier had been working on CF 
mutations at a molecular and cellular level. Her team had observed some patients in 
Europe, of North African descent, who carried the S549R CF mutation, yet appeared 
to have mild clinical disease. The resultant cooperation produced a paper with a very 
interesting finding. I have included the full text of this paper later in this Chapter 
(Section II) as it was published in 1999. 
 
Section I 
Mild Clinical Phenotype Associated with R1158X/S549R (T→G) CFTR 
Genotype1 
 
CF is due to variations that modify the sequence, structure, function and/ or 
expression of the cystic fibrosis transmembrane conductance regulator (CFTR) gene2. 
Besides ∆F508 (which accounts for 66% of all CF chromosomes studied so far), more 
than 1000 other CF-causing mutations have been identified worldwide in the CFTR 
gene3. This allelic heterogeneity partly explains the remarkable clinical heterogeneity 
of CF. Specific mutations, however, have been also reported to be associated with a 
wide spectrum of clinical manifestations. Genotype-phenotype correlation analyses 
thus contribute to providing unique information on the unravelling of CFTR function, 
prognostic evaluations and optimal patient management4. We have shown that in the 
UAE, two mutations, ∆F508 and S549R (T→G), account for 88% of CF alleles and 
characterise 95% of the affected CF families referred to us5. All patients that we 
investigated were homozygous for either of the two mutations. Those of Bedouin 
origin were S549R (T→G) homozygotes while those of Baluch lineage were ∆F508 
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homozygotes6. Moreover, the clinical presentation associated with S549R 
homozygosity is quite homogeneous and shows an extreme degree and course of CF 
severity – and may be comparable to that associated with ∆F5086, 7. Reported here is 
the identification of the first compound hetrozygote patient in the UAE, who harbours 
mutations S549R/R1158X in his CFTR gene. This patient presents with a surprisingly 
atypical, mild form of CF. 
 
 
Clinical presentation 
 
 
AM, a UAE national (Emirati), was born in 1984 by a normal vaginal delivery; his 
birth weight was 4.5 kg. He was first referred to a Paediatric clinic at eight days of age 
because of constipation. At 3.5 months of age, he presented with an attack of 
wheezing, a condition which became recurrent. He was at this stage treated as a child 
with bronchial asthma. At the age of three years, he experienced episodic bouts of 
diarrhoea and his stools were reported as greasy and offensive. A sweat test was 
performed at this stage and it revealed a sweat chloride concentration of 105 mEq/L. 
He was treated with pancreatic extract granules at this time. He continued to have 
mild generalised wheezing but there was no evidence of lower respiratory tract 
infection, especially of a bacterial nature. Additionally, no finger clubbing was 
present and radiological examination of his chest was reported as normal. At the age 
of three and a half years he developed a rectal prolapse. This was managed by a 
medical regimen, but subsequently recurred at the age of five years and was 
accompanied by bouts of abdominal pain. Four months later he developed a 
meconium ileus-like syndrome and intestinal obstruction. He underwent surgical 
treatment but the details of this are not obtainable. One sibling was reported to have 
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died from severe lower respiratory infection but a diagnosis of CF was not sought or 
excluded. 
 
The patient’s family are reported to be very non-compliant with prescribed treatment. 
The patient has attended follow-up clinics infrequently over many years and failed 
numerous appointments. Overall, he receives only occasional treatment for bouts of 
lower respiratory tract infection. He has been prescribed pancreatic enzyme 
supplements on the basis of clinical evaluation only based on the presence of frequent, 
greasy and offensive stools. No formal exocrine pancreatic function tests have been 
performed to establish pancreatic sufficiency or otherwise.  His pancreatic extract 
capsules are taken irregularly. 
 
The patient, who is now 16 years old, is in relatively good health, well nourished and 
has developed normal puberty changes. His height was 166 cms. (55%) and his 
weight was 52 kg. (25%). His weight, however, had remained around the 5th 
percentile for the first nine years of his life and had gradually increased to the 25% 
over the last six years. His peak flow has been measured at 400 L/second, but more 
formal spirometry had not been performed by the supervising doctor. Current physical 
examination revealed a youth without finger clubbing, with a few scattered 
crepitations in his chest and an occasional cough but who was otherwise generally 
well. 
 
CFTR mutations 
 
A blood sample was taken for CFTR genotype determination at age 15 years. The 
patient’s DNA sample was extracted from leukocytes isolated from 5 ml of venous 
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blood collected in EDTA tubes. DNA extraction and detection of CFTR mutations 
were carried out according to the experimental protocols that we have described 
previously5. Results indicated that AM is a compound heterozygote harbouring 
mutation S549R (T→G) in exon 11 of one CF allele and the nonsense mutation 
R1158X in exon 19 of the other allele8. 
 
Discussion 
 
We had to date observed that, in the UAE, mutations ∆F508 and S549R (T→G) 
accounted for 88% of CF chromosomes and that CF patients were homozygous for 
either of the two mutations. Moreover, the clinical phenotypes associated with both 
mutations are quite homogeneous and extremely severe6, including dramatic losses of 
pulmonary function7,  
 
The patient described here is the first compound heterozygote that we have 
characterised as part of our programme on CF in the UAE. Moreover, his 
R1158X/S549R (T→G) CFTR genotype is associated with an atypically mild course 
of the disease. 
 
R1158X had originally been reported as a rare mutation with, for example, one allele 
reported in Spain9 and Portugal10, and two alleles in southern France11 and Canada12. 
Recently, it has been observed that its frequency is higher in Greece, where it is found 
to constitute 0.8% of CF mutations13 and in southern Italy, where it forms 1.3% of the 
total CF mutations14. Genotype-phenotype correlations for this mutation have 
indicated that R1158X homozygosity underlies a very severe expression of CF14 and a 
patient with ∆F508/R1158X genotype had experienced several complications of the 
disease12. Thus, although a patient with R1158X/S549R (T→G) genotype could have 
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been expected to present with severe clinical manifestations, we find that this was not 
the case. The fact that the Emirati patient investigated lives in and has experienced the 
same environmental and medical conditions as the subjects that we have studied 
before5-7 prompts us to believe there must be attenuating genetic factors. Indeed, 
Duarte et al.10 have reported that a complex allele containing two mutations, R334W 
and R1158X, is associated with reduced levels of correctly processed mRNA and also 
that a patient with the complex genotype R334W-R1158X/∆F508 presented with 
pancreatic sufficiency and an atypical course of CF. It has also been shown that the 
sequence change –102(T→A) in the CFTR minimal promoter attenuates the clinical 
severity of mutation S549R (T→G), so that the complex allele [-102(T→A) + S549R 
(T→G)] is associated with milder forms of CF than allele S549R (T→G) alone15. Yet, 
AM’s DNA does not have mutation –102(T→A), Moreover, we have so far, failed to 
identify any additional mutation after screening both parents’ DNA for any of the 31 
most frequent mutations detected by the OLA CF kit (Perkin-Elmer) and scanning 
CFTR exons 3-6a, 7-15 and 17b-23 by polymerase chain reaction/ denaturing gradient 
electrophoresis method described by Costes et al.16. Nonetheless, we cannot exclude 
the possibility of an additional DNA variation that could contribute to the observed 
phenotype effect. 
 
Although almost all of the previously analysed nonsense CFTR mutations have been 
associated with either considerable transcript reduction or production of aberrant 
transcripts (skipping)17, an explanation for the mild phenotype might be that the 
transcript corresponding to the R1158X allele is stable and correctly spliced. Such a 
mechanism may be supported by the fact that there was no exon skipping or 
instability in the case of mutation R1162X as described in three patients who were 
unrelated17. It has, therefore, been suggested that a non-standard decoding mechanism 
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(e.g. readthrough) may contribute to alleviate the molecular consequences of the 
mutation (CF patients carrying R1162X have, in fact, milder pulmonary 
presentations). As the R1158X mutation is located four codons upstream from codon 
1162, it could be associated with the same non-standard decoding mechanism that 
rescues the message and thus produces milder symptoms. The extent of the rescue 
may depend on CFTR-independent transacting elements and account for inter- and 
intra- familial phenotype variations. It will be very informative to examine CFTR 
transcripts in this patient. 
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Section II 
 
The paper below is a reproduction of that published in Human Genetics. I t is included 
to illustrate another modifying mechanism altering clinical severity. 
 
 
Complex allele [-102T→A + S549R (T→G)] is associated with milder forms of 
cystic fibrosis than allele S549R (T→G) alone15. 
 
 
 
CF is a generalised exocrine disorder characterised by a highly variable clinical 
presentation involving the pulmonary, digestive and reproductive systems2. Both 
severity of the disease and rate of progression of CF show an extreme heterogeneity; 
some variation may result from the type of mutations of the CFTR gene. Besides the 
existence of over 800 different CFTR gene defects3, the complex clinical 
heterogeneity in CF might be further explained by possible interactions between 
mutations, as well as with environmental and other genetic modifiers. A number of, 
studies, however, have now demonstrated a strong (although not absolute) correlation 
between pancreatic status and CF genotype. Indeed, pancreatic insufficiency is 
associated with one or two “mild” mutations (of classes 4 or 5) and a milder 
phenotype18, 19. The involvement of specific CFTR genotypes in the variability of lung 
disease is still poorly understood, as a wide range of severity is observed even in 
patients with identical CFTR genotypes. Discrepancies between anticipated and 
observed phenotypes are commonly attributed to “modifier genes” but the possibility 
of multiple sequence variations on the same allele has received little attention20. 
Indeed, in almost all laboratories, genetic analysis is usually considered complete 
when two mutations have been found. Improved strategies and techniques for 
scanning the CFTR sequences, however, have contributed to identify several alleles 
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containing more than one mutation. Such additional second site alterations can 
modulate the effects of the main mutation21, 22. 
 
Recently, we evidenced a novel combined CF allele containing a previously described 
missense mutation S549R (T→G) in exon 11 and a first putative regulatory mutation 
in the minimal CFTR promoter region (-102T→A)23. This complex allele [-102T→A 
+S549R (T→G) was identified in two unrelated patients from Southern France, both 
considered as having a mild form of CF. Mutation S549R (T→G) alone, first 
described by Kerem et al24 in a Moroccan-Jewish patient, has since been shown to be 
associated with very severe clinical phenotypes in all children reported to date 5, 6, 24.  
 
In order to better understand the discrepancy between the phenotypes presented by 
patients carrying mutation S549R, we have conducted a collaborative study aimed at 
comparing ethnic, clinical and genetic data of patients with this mutation. We report a 
genotype-phenotype correlation analysis in six patients carrying the [-102T→A + 
S549R (T→G) complex allele and in 16 patients homozygous for S549R (T→G) 
alone. 
 
Methods and materials 
 
Recruitment of CF Patients 
 
A total of 22 CF patients from the Mediterranean basin (France, Spain) [4 females and 
2 males] and Arab countries (Oman, UAE) [10 females and 6 males] were recruited 
for the study. Mutation S549R (T→G), which accounts for less than 0.5% of 27,177 
CF European chromosomes, has been reported to have a relatively high frequency in 
Algeria (2.6%)27. Recently, Frossard et al.5 showed that it had a very high frequency 
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in the United Arab Emirates, where it appears as the major CF mutation and accounts 
so far for 100% of 20 CF chromosomes from unrelated Bedouin families. 
 
Clinical variables taken into account in this study included gender, current age, age at 
diagnosis, first clinical symptoms, sweat chloride concentrations, weight, height, 
Schwachman-Kulczcki general status score (100 is the best score), forced expiratory 
volume in 1 second (FEV1), forced vital capacity (FVC), lung colonisation with 
bacterial pathogens and age at onset, history of meconium ileus and pancreatic status. 
 
DNA analysis 
 
Specific analysis of sequence (-102T→A) was performed in all 22 patients by 
scanning the minimal CFTR promoter region using a DGGE assay from genomic 
DNA. PCR products that gave abnormal migration were subsequently sequenced on 
an ABI 377 automated sequencer with specific primers23. This allowed the detection 
of alteration (-102T→A) in 6 unrelated CF patients. In all cases, careful familial 
segregation studies showed that (-102T→A) was associated in cis (on the same allele) 
with mutation S549R (T→G). 
 
Haplotype analysis 
 
Sufficient DNA samples from individuals carrying the complex allele only were 
available for further genotyping. Six intragenic CFTR polymorphic sites (IVS8 (T)n, 
M470V, 3601-65C/A and microsatellites IVS8CA, IVS17BTA, IVS17BCA) and four 
exragenic restriction fragment length polymorphisms (RFLPs) (XV-2c, KM.19, J44, 
J3.11) were analysed by appropriate methods, after amplification by PCR. Whenever 
possible, haplotypes were determined by familial segregation analysis. In two cases, 
microsattelite haplotypes were derived from previous studies. 
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Statistical analysis 
 
All quantitative variables were expressed as mean +/- standard deviation (SD) and /or 
as median (with associated ranges). Data from patients homozygous, or compound 
hetrozygous, for the [-102T→A + S549R (T→G)] complex allele were pooled (n = 6) 
and compared with all 16 matched patients homozygous for mutation S549R (T→G) 
alone. In the case of nonparametric variables with non-normal distribution (current 
age, age at diagnosis, sweat chloride values and Shwachman-Kulcycki score), Mann-
Whitney tests were used to assess differences among both groups. Categorical 
variables (age at onset of lung clonisation by Pseudomonas aeruginosa and pancreatic 
status) were analysed by Chi-squared and Fisher exact tests, respectively. All 
statistical analyses were performed with an SAS statistical software package. 
 
Results 
 
Sixteen patients from Oman and the UAE were found to be homozygous for mutation 
S549R (T→G) alone (Table 13). None of the children had presented with meconium 
ileus at birth, but all were pancreatic insufficient and had a very severe lung disease 
with a high rate of Pseudomanas aeruginosa and Staphylococcus aureus infections 
occurring at a very early age and a rapid pulmonary decline. Three of them died of 
pulmonary failure, two at five months and one at 6.5 years of age. Due to the young 
age of the patients, FEV1 and FVC could not be performed and the severity of the 
lung disease was confirmed by radiological analysis7.  
 
In six CF patients from France and Spain, an additional sequence variation (-
102T→A) was identified on S549R (T→G) alleles (Table 14). Five patients were 
compound heterozygotes for the complex allele and another mutation, two with 
∆F508 and three with, respectively R334W, G542X or S945L, one patient was 
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homozygous for the [-102T→A + S549R (T→G)] complex allele. Almost all the 
patients carrying the double mutant allele who were investigated so far have a mild to 
moderate cystic fibrosis presentation (Table 14). Both markers of pulmonary function, 
FEV1 and FVC indicate that lung disease among these patients is relatively attenuated 
except for patients P2 in whom FEV1 and FVC are 19.3% and 38.7% respectively. 
This patient was genotyped for CFTR mutations at 34 years of age because of 
dyspnoea and bilateral bronchiectasis but had normal sweat tests. Interesting also is 
the case of patient P4, who was diagnosed with CF at two months of age because of 
recurrent airways infections. She had no further medical follow-up for CF for more 
than 22 years, until a sudden deterioration of pulmonary function lead to a pulmonary 
transplantation at age 23. 
 
The overall CF status of most patients carrying [-102T→A + S549R (T→G) has been 
considered as mild by their physicians. In agreement with this observation is the case 
of the unique patient who is homozygous for the complex allele. This patient, 
diagnosed at six years of age for episodic bronchitis, is the product of a 
consanguineous mating between first cousins from Algeria. She presents with a very 
mild disease at the age of 34 years and is considered as almost pancreatic sufficient by 
her physician. 
 
Clinical features of the six patients carrying [-102T→A + S549R (T→G)] were 
compared with those of the sixteen children homozygous for S549R (T→G) alone 
(Table15). Age at diagnosis was higher in the first group, although the difference was 
not statistically significant, most probably due to the small size of the cohorts. Current 
age of the patients was higher in the group with the complex allele (p = 0.0032). No 
significant differences were found when comparing Pseudomonas aeruginosa 
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colonisation in both groups. A statistically significant lower age of the onset of 
Pseudomonas colonisation, however, was found in the group with the [-102T→A + 
S549R (T→G) complex allele (p = 0.0022). Fifty percent of patients carrying the (-
102T→A) sequence alteration were pancreatic insufficient as opposed to 100% of 
S549R (T→G)/S549R (T→G) patients (p = 0.013). Sweat chloride concentrations 
were significantly lower (p = 0.028) and Shwachman-Kucycki scores were 
significantly higher (p = 0.004) in the [-102T→A + S549R (T→G)] double mutant 
group. 
 
A common extended [-102T→A + S549R (T→G)] haplotype could be derived in 
almost all CF patients who were studied (Table16). 
 
Discussion 
 
Mutation S549R is a serine to arginine change resulting from a T-to-G substitution at 
nucleotide 1779, a site included in a six-amino acid region defined as “C consensus”, 
which appears to be a unique feature of the ABC transporter superfamily26. As serine 
549 is a highly conserved amino acid in the first nucleotide-binding domain of the 
CFTR protein, its alteration is expected to cause a severe clinical presentation24. 
Previous functional in vitro assays for CFTR activity27 have shown that the R549 
mutant failed to yield the fully glycosylated form of the protein, which subsequently 
failed to traffic to the correct cellular location, as also occurs with the ∆F508 mutant. 
S549R was originally considered as a “severe” mutation with respect to pancreatic 
insufficiency. It has been classified as a class II mutation (defective protein 
processing)18. Three other changes occurring at the same residue, S549R (A→C)28, 
S549N (G→A)29 andS549I (G→T)24, have all been reported as severe. In addition, 
recent studies have evidenced that clinical features associated with S549N (G→A) 
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and S549R (T→G) homozygosity (in Pakistan and the UAE respectively) were quite 
homogeneous and showed an extreme degree and course of CF severity30, 6. 
 
To date, the nucleotide change (-102T→A) has only been found to occur in 
combination with the mutation S549R (T→G), and only on CF chromosomes23. 
Investigations of haplotypes with both intragenic and extragenic markers suggests that 
allele [-102T→A + S549R (T→G)] has a single origin in the families analysed here. 
 
Most CF patients carrying the complex allele were diagnosed at a much later age, had 
pancreatic function relatively well preserved, a milder lung disease and a better 
overall clinical course, compared with the patients carrying S549R (T→G) alone. AS 
no other sequence alteration was found in the coding sequence of the CFTR, these 
observations suggest that the promoter change (102T→A) may lead to milder CF 
phenotypes in patients carrying the severe mutation S549R (T→G). 
 
A few reports have drawn attention to the existence of complex genotypes and to their 
possible involvement in the phenotypic expression of disease-causing mutations. They 
provide a unique opportunity to study the effects of two in cis-interacting gene defects 
on gene expression. For instance, the missense mutation R553Q when carried on a 
∆F508 allele, has been shown to be associated with almost normal sweat electrolyte 
values in a patient with severe CF21, suggesting that R553Q may partially suppress the 
∆F508 chloride transport defect in sweat glands of this patient. It was later 
demonstrated in a yeast expression system model that the abnormal folding produced 
by ∆508 could be partially corrected by the additional, “revertant” mutation R553Q22. 
Because the majority of maturation-incompetent mutants (such as ∆F508 or R549) 
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retain at least some residual function, procedures that would allow a proportion of 
CFTR mutant proteins to escape the quality control machinery at the endoplasmic 
reticulum, could form the basis for therapeutic strategies. Importantly, Brown et al31 
showed that “chemical chaperones” that stabilise protein structure, such as glycerol, 
have the ability to restore normal trafficking behaviour of the ∆F508-CFTR protein. 
As suggested by Seibert et al.32, another way that enables some proteins to escape 
from the endoplasmic reticulum is the flooding of the control machinery by 
stimulating over-expression. Chemical agents such as sodium butyrate have been 
reported to promote ∆F508-CFTR movement to the cell surface at levels that are sub- 
wild-type33. Consistent with this latter approach, it is tempting to speculate that the (-
102T→A) sequence alteration in the minimal CFTR promoter could stimulate the 
CFTR expression at sufficient level to partially compensate the S549R (T→G) 
molecular defect. To test this hypothesis, in vitro and in vivo expression studies are 
now in progress. 
 
In summary, the combined allele [-102T→A + S549R (T→G)] appears to be 
associated with a better prognosis of CF disease, suggesting that the (-102T→A) 
modification in the CFTR promoter may, at least partially, compensate the severity of 
mutation S549R (T→G). In agreement with previous studies, our findings further 
support the idea that double mutant alleles may be more common than expected and 
could influence the status of clinical phenotypes. Such complex alleles would thus 
have important implications for molecular diagnosis and genetic counselling. 
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Table 13 
 
Clinical characteristics of 16 patients homozygous for the S549R (T→G) 
mutation 
 
 Character
 
is ien               
               
                 
                
                
             
 
              
       
                  
                  
                
                
   
                
                
tic Pat
 
t 
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16
Genotype S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R S549R
Geographic 
background 
 
Oman UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE UAE
Sex F F M F F F F M M F M F F F M M
Ethnicity Arab
 
Bedouin
 
 Bedouin
 
 Bedouin
 
 Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin
 
Bedouin 
 Current age - 4 9 - 12 8.5 5 3 7 2 10 5 3 2 - 2
Age at death 5 
months 
- - 6.5 - - - - - - - - - - 5
months 
- 
Age at 
diagnosis 
3 
months 
 
6 
months 
 
2 years 1 year 4 
months 
 
8 
months 
 
8 
months 
 
3 
months 
 
3.5 
years 
3 
months 
 
3 years 1 year 3 
months 
 
3 
months 
 
1 month 1 month 
Sweat Cl- 
(mmol/l) 
70 120 123 155 133 100 150 120 150 100 120 90 90 120 ND ND
Height % >10 10 5 5 5 25 25 <10 <10 <10 <10 <10 <10 <10 <10 <10
Weight % >3 5 5 5 5 10 25 <10 <10 <10 <10 10 <10 <10 <10 <10
Shwachman 
Kulcycki 
Score 
 
ND 60 55 45 50 55 40 55 45 55 45 60 55 45 35 50
Lung 
colonisation 
Yes No Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes Yes
Pseudomonas 
aerg. 
Age at onset 
5 
months 
- 5 years 1 year 4 
months 
8 
months 
1.5 
years 
- - 3
months 
3 years 1 year 3 
months 
3 
months 
1 month 1 month 
Meconium 
ileus 
No No No No No No No No No No No No No No No No
Pancreatic 
insufficiency 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
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Table 14 
  
Clinical characteristics of six patients carrying the complex allele [-
102T→A + S549R (T→G)] 
 
Characteristic
 
 Patient      
      
 
    
        
       
       
        
      
        
        
      
      
       
      
P1 P2 P3 P4 P5 P6
Genotype -102T→A + S549R 
(T→G)/ 102T→A + 
S549R (T→G) 
102T→A + S549R 
(T→G)/R334W 
102T→A + S549R 
(T→G)/∆F508 
102T→A + S549R 
(T→G)/∆F508 
102T→A + S549R 
(T→G)/G542X 
102T→A + S549R 
(T→G)/S945L 
Geographic 
background 
South of France South of Spain South of France North of France North of France South of France 
Ethnic background 
 
Jews of Algeria 
 
Unknown Jewish Unknown North African 
 
Jewish 
Sex F F F F M M
Current age (years) 34 38 6 31 23 18
Age at diagnosis 6 35 3.5 2 months 4 months 9 
Age at first clinical 
symptoms 
5 Unknown 3 2months 4 months 5
Sweat Cl- (mmol/l) 
 
Unknown <60 122 66 72 85 
Height % 60 50 Unknown 60 26 30
Weight % 60 50 Unknown 40 12 <25
Shwachman 
Kalczycki score 
85 Unknown 85 Unknown 60 85
FEV1 % 30 19.3 89 60 59 89
FVC % 50 38.7 96 100 76 115
Lung colonisation Yes No Yes Yes Yes Yes
Pseudomonas aerug. 
(age of onset) 
12 - 3.5 22 11 9
Meconium ileus No No No No No No
Pancreatic 
insufficiency 
 
Yes (minimal) No No Yes (minimal) Yes No 
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Table 15 
 
Comparison of clinical features between CF patients carrying the 
complex allele and those carrying S549R (T→G) alone 
 
Feature  Patients with[-
102T→A + S549R 
(T→G) n = 6 
 Patients with S549R 
(T→G) n = 16 
 P value 
 Mean +/- SD Median (5th – 95th %) Mean +/- SD Median (5th – 95th %)  
Current age (years) 25+/- 11.8 27 (6-38) 5 +/- 3.35 5 (2-12) 0.0032 
Age at diagnosis 
(years) 
9 +/- 13.2 4.75 (0.16-35) 0.88 +/- 1 0.41 (0.08-3.5) NS 
Sweat Cl- (mmol/l) 79 +/- 27.13 72 (50-120) 117.2 +/- 25.1 120 (70-155) 0.028 
Shwachman-Kulczcki 
score 
78.8 +/- 12.5 85 (60-85) 50 +/- 7.3 50 (35-60) 0.004 
Age at onset of lung 
colonisation  
11.5 +/-6.7 11 (3.5-22) 1 +/-1.43 0.41 (0.08-5) 0.0022 
Lung colonisation 
(number 
positive/number 
studied) % 
5/6 83  13/16 81  NS 
Pancreatic 
insufficiency (number 
positive/number 
studied) % 
3/6 50  16/16 100  0.013 
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Table 16 
 
 
CFTR haplotypes for seven [-102T→A + S549R (T→G)] chromosomes 
 
 
 
Patient            
 
           
           
            
           
           
            
      
           
            
      
           
            
           
           
            
           
Genotype XV2c KM9 J44 IVS8CA IVS8(T)n M470V IVS17BTA
 
IVS17BC 360165C/A J3.11
P1 [-102T→A + S549R (T→G)          
 
1 2 1 23 7 1 34 13 1 1 
[-102T→A + S549R (T→G
 
1 2 1 23 7 1 34 13 1 1
P2 [-102T→A + S549R (T→G)
 
1 2 1 23 7 1 34 13 1 1
R334W
 
2 1 2 17 7 2 46 13 1 1
P3 [-102T→A + S549R (T→G)
 
1 2 1 23 7 1 34 13 1 1
 ∆F508
 
1 2 231 9 1 31 13 1 1
P4 [-102T→A + S549R (T→G)
 
1 2 1 23 7 1 34 13 1 1
 ∆F508
 
1 2 231 9 1 32 13 1 1
P5 [-102T→A + S549R (T→G)
  
1 2 1 23 7 1 34 13 1 1
G542X
 
1 2 1 22 9 1 33 13 1 1
P6 [-102T→A + S549R (T→G)
 
1 2 1 23 7 1 34 13 1 1
S945L 2 1 2 16 7 2 29 13 1 1
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Overview 
From the information presented in the two research papers it is clear that the CF 
mutation S549R (T→G) is not invariably associated with a severe clinical disease. 
Even in the homozygous state it is not always so, but to date, we have not encountered 
a patient in the UAE with the additional promoter mutation which can alter biological 
events and eventually end in the production of a milder clinical disease. All patients 
have been tested in France, however, for this possibility. It is of interest that the 
“European” patients with the additional complex were of North African origin in the 
main and one was of Arab descent. It is of further interest that three patients were of 
Jewish background and that the original patient with S549R (T→G) mutation, 
described by Kerem and Kerem, was of North African Jewish descent like these 
patients. I later postulate that the origins of the S549R (T→G) may have been from 
the Yemen. At one time this country had a large and well integrated Jewish 
population who have subsequently moved to Israel. This former close integration may 
have resulted in some interesting genetic alterations. Unfortunately there is no 
information available about CF and its mutations from the Yemen. My own 
observations there revealed continuing evidence of the former Jewish population who 
had lived closely with the Moslem people. Many homes still carry Jewish symbols 
and evidence exists of the famous Jewish silversmiths and their products. Former 
synagogues are converted to Mosques. 
 
 
The strict control of permanent resident visas and citizenship in the UAE makes it 
highly unlikely that further studies will reveal a large pool of heterozygote 
combinations within the UAE. However, we have encountered a ∆F508 homozygote 
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CF child who is an offspring of Syrian parents who have been given UAE citizenship. 
Similarly, a UAE citizen who is the child of an Arab father and a Pakistani mother has 
CF due to the mutation 3849 + 10Kb C→T/G628R. 
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Chapter 12 
 
 
Cystic fibrosis in Omani Children 
 
 
“The only trouble is, we  
  can not understand what is happening to our neighbours” 
 
Speech, Smethwick, 18th January 1906 
Joseph Chamberlain (1836-1914) 
 
 
In Chapter 10, I drew attention to the observation of cystic fibrosis in an Omani child, 
the first that we had encountered. While visiting Muscat, Oman to take part in a 
Paediatric Conference and to present data on CF in the UAE, I discussed the CF 
situation in Oman with colleagues there. Most Omani Specialist Paediatricians had 
trained in Western countries and were familiar with CF as it presents in the West.  
Further, the well-organised health system in Oman meant that complex patients with 
conditions like CF will be referred to one of the two Teaching Hospitals in Muscat, 
the capital. While the two countries, which form the Eastern Arabian Peninsula, have 
much in common there are sufficient ethnic and racial differences to make a close 
study of CF there of interest. It was agreed among the small group of interested 
clinicians that we would undertake an investigation into the presence of CF in Oman 
using the same protocols that had been used in the UAE. In addition all genetic 
studies would be performed in Al Ain, UAE in the University Department, using the 
same methods as described in this text. This Chapter therefore, contains the first 
observations on, CF, as it presents in Oman, and have lead to the first publications on 
the topic to appear in the medical literature. 
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We set out to answer two questions initially. The first was whether CF mutations in 
Oman were different to those in the UAE, and if not which were the common 
mutations associated with the disease in the Sultanate (Section I). The second related 
to the assessment of the clinical presentation and the severity of the condition in 
Omani children (Section II) with confirmed disease. 
 
 
Section I 
Identification of cystic fibrosis mutations in Oman1 
 
Introduction 
Table 6 supports the view that each Arab country has an individual range of CF-
causing mutations. Oman is one of the UAE’s neighbouring countries and shares 
some common genetic influences. The indigenous population of Oman is principally 
composed of Omani nationals who belong to different tribes that are all of Bedouin 
origin. Other genetic influences, however, have come from many diverse places. 
These include Yemen, East Africa, Iran and especially Baluchistan. 
 
Subjects and methods 
 
Mutational analysis was performed on 15 Omani families, which included 16 children 
suffering from CF (Table 17). Family names (corresponding to original tribal names) 
and detailed family histories allowed us to establish that 12 of the 15 families 
(including 13 patients) originally belonged to true Omani Bedouin tribes. Three other 
families were Omani nationals of Baluch (Pakistani) origin. Patient ages ranged from 
infancy to 8 years. 
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 CF diagnosis was based, in all patients, on the typical clinical presentations including 
high sweat chloride concentrations. All patients had sweat chloride levels ranging 
from 90 to 130 mmol/l. 
 
Patient DNA samples were extracted from leucocytes isolated from 2 ml of venous 
blood collected in EDTA tubes. DNA extraction and detection of mutations ∆F508 
and S549R (T→G) were carried out according to the experimental protocols that were 
described previously. 
 
 
Results and Discussion 
 
The data presented in Table 17, indicates that, of the 16 CF Omani patients, 11 (two 
affected siblings and nine CF children from nine other families: age range: 4 months 
to 11 years) were homozygous for mutation S549R (T→G). All of these 11 patients 
were of Omani Bedouin descent and their sweat chloride concentrations ranged from 
121 to 130 mmol/l. Two unrelated CF patients, who were of Baluch descent, were 
homozygous for the ∆F508: their sweat chloride levels were 109 (a one-year-old) and 
127 (1.5-year-old) mmol/l. At this point, three patients (two Omani Bedouins and one 
Omani of Baluch descent) have other CFTR mutations that have not yet been 
identified. Their sweat chloride levels, however, were lower (90-117 mmol/l) and 
their ages ranged between three and eight years. 
 
Considering the relatively small number of cases in this study, one has to remain 
cautious with the data interpretation. We have shown here, however, that the two 
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mutations ∆F508 and S549R (T→G) allow the characterisation of, respectively, 13% 
and 73% of CF families (12.5% and 69% of patients). Therefore, the combination of 
both mutations allows the detection of 87% of CF families and 81% of CF patients. 
The pattern of distribution of CF mutations found in this study from Oman is thus 
very similar to that observed in the UAE. Anecdotal observations from colleagues, 
however, seem to indicate that there is a lesser degree of genetic homogeneity in 
Oman. 
 
The relationship of ∆F508 mutation in the homozygous state to Baluch origin appears 
to hold true for Oman as well as the UAE. The close ties of Oman to Makram in 
Baluchistan are discussed in the next chapter. 
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Table 17 
 
Distribution by ethnicity and by ethnic origins of CF patients and families that 
were recruited and the number of alleles carrying either of the two mutations 
S549R (T→G) and ∆F508 
 
 
 
 
 
Ethnic 
origin 
Number of 
families 
Number of 
patients 
Mutation Number of 
CF alleles 
     
Bedouin 
descent 
12 13 S549R (T→G) 22/26 
Baluch origin 3 3 ∆F508 4/6 
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Section II 
 
The finding that the mutational pattern in the sample of Omani patients is similar to 
that of the UAE patients that have been assessed poses the question as to whether the 
clinical presentations are similar. It should be remembered, however, that all the 
patients seen in the Emirates where under my clinical care. Thus, the protocols for 
management are standardised and based upon the currently published CF management 
guidelines used in the Western countries. The Symptomatic therapy used is founded 
on the current published knowledge such as that reviewed recently by Ratjen and 
Döring3. Similar standard treatment plans were not in place in Oman, hence a 
comparative outcome study could not be carried out. 
This section then reports the clinical features and available mutational information on 
a larger group of Omani children with CF. 
 
Cystic fibrosis in Omani children: clinical features and genotypes2 
 
 
Subjects and methods: 
Omani children in whom a diagnosis of cystic fibrosis has been established were 
included in the study group. They were attending, either the Royal Hospital, Muscat, 
the Sultan Qaboos University Hospital, Muscat after referral from elsewhere in Oman, 
or they had been referred to the CF clinic at Tawam Hospital, Al Ain, United Arab 
Emirates (UAE) from neighbouring parts of Oman. Included were the group of 16 
children described in Section I who had been studied in relation to their CF mutations. 
 
Clinical data was collected on age at diagnosis, demographic details, sweat electrolyte 
levels, measures of clinical severity (Shwachman Score14), Pseudomonas colonisation 
rates, lung disease, pancreatic function and evidence of previous meconium ileus, 
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genotype information and details of any parental consanguinity. The patients' DNA 
was screened for the 31 most frequent mutations detected by the OLA CF kit (Perkin-
Elmer). 
 
Results: 
Thirty children with cystic fibrosis were identified, (14 males and 16 females). Nine 
families gave a family history compatible with CF. The thirty children were drawn 
from 26 unrelated families. All families were Omani nationals but four families were 
of Baluch descent and the remainder was of Bedouin descent. 
 
Table 18 outlines the clinical details of the patients indicating that overall they have a 
mean sweat chloride level of 105 mmol/L. Table 19 shows that the S549R (T>G) 
mutation was the commonest CF mutation identified. The families of seven children 
declined to have mutational analysis performed. 
 
Discussion: 
The Hospitals in Muscat serve as the tertiary referral centres for the Sultanate. The 
patients were drawn from a wide geographic area within Oman. Consanguinity was 
present in 42% of the families, and this was at first cousin level. 
 
The clinical disease manifestations indicated that the disease process is severe in 
Oman, with one third of the patients having established chronic lung disease with 
Pseudomonas colonisation being present in most of these. This is despite early 
diagnosis and ready access to free treatment within the country. Pancreatic 
insufficiency was present in all but one of the patients in whom the genotype has been 
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established, and in all the seven patients in whom we have not as yet identified the 
actual mutations. It is of interest that three patients have had a clearly documented 
episode of meconium ileus, which lead to an early diagnosis. Two of these patients 
were homozygous for the S549R (T→G) mutation and are the first that have been 
documented with meconium ileus associated with this mutation5. 
 
Sweat chloride levels are very high in all but two patients. These two belong to the 
unidentified mutation group but they do have pancreatic insufficiency. The mean 
Schwachman Scores4 are within the moderate range of disease severity but within this 
group there are several severe patients. More importantly the mean age of the group 
was only 4.4 years, thus despite early diagnosis and treatment disease progression 
continues.  
 
The identified genotype distribution is very similar to that found in the neighbouring 
United Arab Emirates with mutation S549R (T→G) being found in the majority of 
patients, but contrasts dramatically with that reported from Saudi Arabia6, 7. Again, as 
in the UAE, the three patients homozygous for ∆F508 mutation were both Omanis of 
Baluch descent. It is clear that there are major variations within the Arabian Peninsula 
in terms of genotypes. Within the UAE and Oman the S549R (T→G) mutation 
dominates, the I1234V is universal in Qatar8 and a different and wide range is found 
in Saudi Arabia with at least 17 different CFTR mutations having been described, 
none being dominant however6, 7. 
 
CF children are widely distributed throughout Oman. The disease pattern in the 
sample of patients presented is severe. Meconium ileus associated with S549R 
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(T→G) mutation has been recognised for the first time in two patients. Genotypes 
recognised to date are similar to the UAE, but there may be novel mutations still to be 
identified. 
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Table 18 
 
The Clinical Details of 30 Omani Patients 
 
 
 
 
 
 
 
 
 Mean ± SD Range 
    
Sweat chloride mmol/L 105 29.8 27-140 
Schwachman Score 64 12.5 41-90 
Current age (in years) 4.4 3.5 1-14 
Age at diagnosis (months) 11.8 10.7 3-48 
 
n = 30 
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Table 19 
 
Genotype and Phenotype distribution in 30 
CF patients 
 
 
 
 
 
 
Genotype             R549/    
R549 
∆F508/   
∆F508 
Not 
Identified 
Not 
Performed 
     
Number of Patients 13 3 7 7 
Chronic lung disease 5 0 3 2 
Pseudomonas  colonisation 5 0 0 2 
Meconium ileus 2 1 0 1 
Pancreatic insufficiency 12 3 7 2 
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Overview   
It is clear from the studies reported above, that the pattern of identified mutations is 
similar in the UAE and Oman. However, seven patients to date, have not had their 
specific mutation defined. This may well be explained by there being novel mutations 
present or that we simply have not been able to define them as yet. From the data 
presented from the UAE, the longer we have studied patients and the increasing 
number identified the more interesting and unusual are the findings that emerged. I 
suspect that this holds good for Oman also. 
 
The pattern of immigration to Oman from the Baluchistan geographic area is again 
similar to the UAE. All patients had the ∆F508 mutation and were homozygous. This  
raises some interesting possibilities and has led to an hypothesis about the origins of 
the mutation. These ideas are presented in Chapter 13. 
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Figure 26 Three children 
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Chapter 13 
 
Hypotheses regarding the origin and 
spread of the cystic fibrosis mutations 
S549R (T→G) and ∆F508 
 
 
“Read no history: nothing but biography, 
  For what is life without theory” 
 
Contarini Fleming Part 1 Chapter 7 
Benjamin Disraeli (1804-1881) 
 
 
 
In this section I present two hypotheses. The first concerns the S549R mutation, 
which is speculation, based on some historical facts. My input was to visit the relevant 
areas in the Yemen and discuss what the traditional feelings were about the links 
between the Yemen and the UAE. The second is a published hypothesis about the 
∆F508 and is reproduced in part below. 
 
The mounting information that had been gathered about the once rare or “private” 
mutation S549R (T→G), permitted me to review what was known of its origins and 
clinical phenotype. From the single initial report in 1990, we have identified over 
sixty alleles carrying the mutation. The location in the Eastern Arabian Peninsula of 
those carrying the mutation does not fit any widely publicised pattern of human 
migration. It does seem to be found mainly in the Bedouin people of Oman and the 
UAE. An historical link does exist between these people and those in the Yemen, 
particularly in the Marib region. Indeed, a dormitory village of Al Ain, UAE has a 
population of purely Yemeni people of many years standing. Marib has been one of 
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the most famous areas in the Republic of Yemen since ancient times. It was well 
known historically as “Arabia Felix” or the “Land of the two Paradises”. A great 
civilisation flourished there under the famous Queen of Sheeba. It was also known for 
the massive and famous Marib Dam. This dam and its irrigation canals suggest that 
the Yemenis were the pioneers of irrigation systems15. The presence of these canals 
allowed agriculture to flourish and wealth to accumulate and a large population to be 
supported. History and tradition state that in this region the collapse of the dam by a 
major earthquake, about one thousand years ago led to a subsequent famine and this 
caused a major disaster. Subsequent resultant emigration of the population occurred. 
To emigrate east involved crossing the Arid Quarter (Rhub al Khali) of the Arabian 
Desert, one of the most treacherous places on earth. To the North lay the Gulf coast a 
sparsely populated area. Certainly, today on visiting Marib, there is an acceptance of 
these close links and of this tradition. I visited also the site of the ruined dam and saw 
the inscriptions in pre-Arabic script. His Excellency Shaik Zayed, the President of the 
UAE, funded the restoration of the Marib Dam and lake. When I visited the region 
and the site of the new dam, I found Shaik Zayed’s portrait and that of the President 
of Yemen dominating the visitors area at the edge of the lake and testifying to the 
strong traditional links between the two countries (see Figures). 
 
I am therefore proposing that the ancestral home of this mutation may be the Yemen. 
The mutation was carried to what is now Abu Dhabi and then on to the remainder of 
Oman by the tribal links of that Emirate to the tribes of northern Oman. There is no 
literature on CF in the Yemen. However, it must be remembered that Yemen is the 
least developed of the Arab countries. Medical care is minimal for those in the desert 
regions and the high mountains of central Yemen make transportation and contact 
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nigh on impossible for the scattered tribes. Political unrest made it necessary for me to 
travel in the Marib region with an army escort and in a military convoy.  
 
A personal communication with Professor El Harith in Saudi Arabia who informed 
me that his group had only identified one patient with the S549R on a single allele. 
Interestingly, this family had originated in the UAE. Thus unlike the UAE the 
mutation is apparently not present in those of Saudi Arabian stock. This adds indirect 
evidence that the migrations from Yemen may have been targeted at the Trucial Coast 
and not the Hejaz or Nejad regions. Ideally, a search for the mutation in Yemen would 
support my hypothesis. Unfortunately this was not possible at that time. 
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Figure  
 
The Lake and Dam at Marib, the Yemen. 
 
The ancestral home of the S549R (T→G) 
mutation? 
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Figure 
Mother and Child in Marib, the Yemen
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An hypothesis regarding the origin and spread of the cystic fibrosis mutation 
∆F508 
 
Morral et al.1 have presented strong evidence that the ∆F508 mutation arose in a 
population genetically distinct from the present European population. Further, data 
plotted on synthetic maps indicates a marked frequency gradient from south-west to 
north-west Europe e.g. 100% presence of ∆F508 in CF mutations in the Faroe Islands 
compared with 27% of all mutations in the Turkish CF population 2.  The explanation 
offered for this phenomenon is that there has been a greater mixing and heterogeneity 
in the southern populations and relative isolation in the northern.  The current view is 
that ∆F508 was not spread by the Indo-Europeans but by a group that preceded them 
and had originated in the “Middle-East" or the "East"1. Bertranpetit and Calafell3 have 
summarised the basis of the estimates of the age of the ∆F508 mutation.  The 1705 
chromosomes studied carried 1477 microsatellite mutations (corresponding to a mean 
λ = 0.866).  A mutation rate of 3.3 × 10-4, gave a total time of 2,625 generations, 
which gives an estimate of 52,000 years.  This is a mean estimate and its standard 
error may be large. 
 
We are thus considering a population based in the East, in which a mutation arising 
some 50,000 years ago, provided some biological advantage to those who were 
carriers.  Currently, some authors have hypothesised that this advantage could be 
considered as a protection from typhoid fever rather than cholera as had formerly 
been suggested.4 
 
In an attempt to determine where in Asia this mutation may have arisen, the study of 
the presence of ∆F508 in Asians living in Western countries has not been very 
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rewarding.  The lack of information from Asian countries has made this method 
necessary.  In a large Asian population, the study of almost 900 chromosomes 
revealed the absence of carriers of the common Caucasian-related mutations 
(including ∆F508).  However, an affected Pakistani child born to consanguineous 
parents was shown to be homozygous for mutation S549N (G→A) 5.  Schwartz et al. 6 
reported six affected Pakistani children, of who three were homozygous for the ∆F508 
mutation.  It was not stated to which ethnic group within Pakistan the children 
belonged.  Further study of Asians with CF was reported by Bowler et al.7, who 
outlined the clinical course in nine Pakistani Asians.  Four of the nine were 
homozygous carriers for the ∆F508 mutation.  A comparison was made with a group 
of 18 Caucasians, 17 of whom carried ∆F508, of which 12 were homozygous.  A high 
degree of consanguinity was reported and a more severe clinical course, which it is 
suggested, may have been influenced by genetic and environmental factors. 
 
In a study from the USA of Asians with CF, 20 patients were identified in US CF 
clinics8.  Seven patients carried the ∆F508 mutation, of which four were 
homozygotes.  Pakistanis represented 10 (probably 11) of these patients, Indians 8, 
and one Palestinian.  Again, no information was given as to the ethnic sub-group of 
the families.  The authors calculated that the incidence of CF in Asians was 1: 40,750 
but noted a figure of 1: 10,000 proposed from the UK 9.  The only study, which gives 
some information about ethnicity within the Indian subcontinent, is that of Spencer et 
al 10, who reported on 13 CF patients.  Seven patients were from Mirpur (Kashmir) 
and one of them was homozygous for ∆F508.  Four patients were Sikhs from the 
Punjab (India) and two of them carried the ∆F508 mutation.  The remaining patients 
were from Bangladesh and a Moslem Punjabi, but their specific mutations were 
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unknown.   Overall, most reports about CF have focused upon Pakistanis and only 
rare reports come from others such as Sikhs and Bangladeshis.  In about half of these, 
the ∆F508 mutation is implicated and is usually found in a homozygous pattern, 
which reflects the extensive consanguinity amongst these ethnicities. 
 
If the founder ∆F508 mutation occurred in Asia some 52,000 years ago and bestowed 
some benefit on that early population, where are the descendants of these early 
people?  It is highly unlikely that they all migrated to Europe, so there should be a 
remnant population, which carries evidence of this genetic descent. 
 
It is proposed that the most likely ethnic group who could provide evidence of this 
decent are the Baluchi people.  They number about 5 million and are located in Iran 
(20%), Pakistan (Baluchistan Province 70%) and Afghanistan (10%).  The original 
Baluchi homeland was said to be the Iranian Plateau and by the 10th Century AD, they 
had migrated to their present location as described in the Arabic Chronicles of that 
time, with migrations continuing into the 14th Century AD 11. Their eventual 
settlement area is an arid region surrounded by the daunting mountain regions of Bag-
e Band and Bampusht.  This region is regarded as one of the most isolated in the 
world 11.  
 
The Iranian Baluchi territory provided a land route to the Indus Valley and the 
Babylonian civilisation.  This route was exploited by Alexander the Great who 
marched through Baluchistan in 326 BC.  Thus the area was in a key position in 
relation to South-West Afghanistan, the Indus Valley, Iran, Iraq and the Levant.  Later 
emigration occurred from Baluchistan into the Punjab of India, as well as to Oman 
and the present UAE. 
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The close geographical location of Baluchistan to the UAE makes it very likely direct 
transfer of the ∆F508 mutation occurred by the well-established sea links.  The 
Baluchi people have remained an isolated group living in a large area (347,190 square 
kilometres) and have practised traditional arranged consanguineous marriages.  It is 
not surprising, therefore, that all the patients we have seen of Baluch descent are 
homozygous for the mutation ∆F508 12.  Similarly, population screening has indicated 
those UAE Nationals of Baluch descent and Pakistanis from Baluchistan living in the 
UAE were similar in their carrier state, i.e. ∆F508 only.  Indirect supporting evidence 
for this hypothesis may be found in the study of Karjoo et al.13.  He investigated 
prospectively and retrospectively all suspected cases of CF in Southern Iran seen in 
the three University hospitals of Shiraz University.  The people studied were living in 
Fars Province adjacent to the Baluchi areas of Iran, but are ethnically different.  The 
investigators could find no previous reports of CF in a 20-year retrospective study or a 
patient with a firm diagnosis of CF.  In the prospective study of 125 suspected 
individuals, only three patients were considered to have the disease on clinical 
grounds.  No genetic studies were undertaken.  Thus is an area close to Baluchistan, 
CF appears to be a very rare disease, yet it is now found regularly in Baluchis.  
Quaife et al. studied the spectrum of the disease beta thalassaemia in the UAE 
national population.  They concluded that specific mutations were introduced into the 
UAE by immigrants from Baluchistan and matched those found in that region.  One 
mutation in particular, the β+ IVSI-5 (G → C), has rarely been found in Arab 
populations elsewhere and appears to have arisen in the Baluchi population 14. 
To gain genetic information about the relation of the early settlers in Europe and the 
present day residents in the UAE of Baluch descent and Pakistani Baluch people a 
study of microsatellite markers on the respective alleles is necessary.  
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The hypothesis proposed here is that the original founder ∆F508 mutation giving rise 
to cystic fibrosis occurred in those inhabiting the Iranian Plateau and travelled from 
there eventually to Europe in the first wave of emigrants.  Their descendants moved to 
the area of Baluchistan bringing the mutation with them.  During the last 150 years, 
further migration has occurred into the Gulf Region and the ∆F508 mutation has 
joined the pool of CF mutations that are common in this region 12, 15. 
                                                          
. 2  This hypothesis was presented initially in a Master of Science (Geography) thesis that was 
accepted by Massey University and also published in the Quarterly Journal of Medicine 
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Epilogue 
It has been proposed in the hypothesis above that the transfer of the ∆F508 mutation 
to Oman and the UAE could have been by the established sea routes across the 
Arabian Sea and Indian Ocean. A very relevant trade network was that between Oman 
and Gwandar. This settlement is situated in the present day Baluchistan area of 
Pakistan (see map Figure 3) and was originally an Omani enclave. It played an 
important role within the slave, ivory and spice trades coming from the Arabian 
Peninsula and East Africa and linking with Central Asia16. This coastal strip had also 
been the main route between the Middle East and the sub-continent. 
 
In the last quarter of the 18th Century, Gwadar and the area of Makran were succeeded 
to the "Masnad" of Muscat in 1783. Prior to this the Portuguese had captured several 
places along the 600 kilometres of Gwadar and Makran coast17. Gwadar remained an 
Omani possession until September 1958, when it was transferred (sold) to Pakistan. 
 
Thus it is possible that this important area provided the ideal route to the Middle East, 
Iran, and Pakistan from and to the Eastern Arabian Peninsula and permitted the 
"transfer" of the ∆F508 mutation to the Arab world from Iran (Baluchistan). 
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Figure 21 Map of Baluchistan 
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Chapter 14 
 
Summary and Conclusions 
 
 
“Rome has spoken: the case is concluded” 
 
Sermons, Book 1 
St. Augustine (354-430) 
 
The content of this dissertation developed as a result of the observation that a dying 
Arab girl had the clinical features of cystic fibrosis. More importantly, her subsequent 
confirmed diagnosis stimulated the development of a clinical and laboratory service 
designed to serve those with cystic fibrosis. 
 
The clinical observation raised many questions. If this was truly CF, is it an important 
disease among Arabs in the Gulf Region and if so how common is it? Certainly, the 
prior medical literature was unhelpful and suggested that the condition was either 
absent or very rare among Arab communities. The overwhelming majority of citizens 
in the UAE are Arabs of Bedouin origin and there were simply no reports of the 
disease occurring in this group of people. However, there were two reports of 
probable CF in two children from the Northern Emirates that had been published in 
the local medical journal. These children, while UAE citizens, were of the Baluch 
ethnic group and were thus not Bedouin Arabs. 
 
This thesis, therefore, supplies the answer to many of the questions that were raised. 
What has been learned in addressing these questions? Probably the most important 
advance has been in establishing beyond doubt that the disease CF does affect Arab 
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children in the UAE and Oman and throughout both countries. It is an important cause 
of serious illness and is much more common than previously appreciated, causing 
much morbidity and almost certainly premature death. With this knowledge I 
established a centre for the diagnosis and management of the condition. This was 
open for referral of children from all areas in the UAE. My colleague, Dr. Phillipe 
Frossard, developed the technical facilities to define the majority of known mutations 
found in the CFTR gene. Thus, in a combination, we were able to provide a basis to 
answer more questions about the background of CF and provide a better clinical 
service. 
 
Clearly, having the information that the condition is more prevalent than previously 
appreciated serves no purpose if it is not acted upon. Our aim was to achieve an 
increased level of awareness and to establish early diagnosis and instigate treatment. 
Certainly experience from Western countries indicates that this is worthwhile in terms 
of quality of life and longevity for the affected children. To raise the level of 
awareness about the condition, I wrote to every Paediatrician in the country informing 
them of our interest, the establishment of a clinic and the facilities in the Medical 
School for mutational analysis. Further, our early results were published in the local 
medical journal and subsequently in international journals. Presentations were made 
at the national Paediatric Society scientific meeting and regional Paediatric meetings. 
Eventually, I made presentations in Lebanon (Middle East and Eastern Mediterranean 
Paediatric Society), Qatar, Bahrain and Oman. Finally, an even wider scope for 
publicity was achieved by a presentation to the Congress of Asian Paediatric Societies 
at its meeting in Taiwan. 
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Not only was CF being recognised in the local Emirati population, there was an 
increasing number of children in total, being referred to the clinic and an increase in 
the numbers being diagnosed as having CF. Referral of children of other national 
groups was taking place. Indeed, we established and confirmed the diagnosis of CF in 
Arab children from Egypt, Palestine, Syria and the Sudan. In addition, children from 
the UK and Pakistan were investigated for CF. However, their clinical details are not 
included in this thesis. However, an example of a delightful non-Emirati Arab boy 
with CF is to be seen in the end figure. 
 
It appeared that the clinical presentation was severe. The prior treatment received by 
individuals obviously influences the disease presentation overall. However, we were 
assessing and confirming the diagnosis in young children and noting early 
colonisation with pseudomonas organisms in many. Information was thus collated to 
support the clinical impression that we were dealing with children with severe 
disease. 
 
If the disease exists and in such a severe form then why is it only now that it is being 
recognised? I have only indirect evidence to answer this question. No UAE adults 
with the disease have been recognised in our area (total population of 400,000). 
Recognition was in terms of hospital records and those attending the adult respiratory 
service. This seems a reasonable assumption in that surviving adults with the disease 
would require hospital facilities and treatments for their management. It can only be 
assumed that those with the disease have died prior to reaching adulthood. I have 
described elsewhere that non-CF bronchiectasis is common in the children of the 
UAE. This situation is well recognised and the adult Respiratory Physicians treat such 
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patients regularly. I can only postulate that many deaths previously have been 
attributed to bronchiectasis and pneumonia. Post mortem examinations are not carried 
out in the UAE for cultural reasons. Only in cases of suspicious death are autopsies 
performed. The other important factor is the harsh environment and climate of the 
area. I have given an example of an infant who could have died from dehydration, 
hyponatraemia and hypochloraemia. She is one of many infants who could have died 
in former times without the underlying disorder having been recognised. CF children 
are, of course, at particular risk of salt loss. Those living in the Gulf States who do not 
have CF are at great risk of salt depletion when ambient summer temperatures can 
reach 48ºC. Above all the medical services in the UAE and Oman have only recently 
reached a minimum standard. This was not due to a lack of funds, but to a lack of 
qualified personnel and a suitable infrastructure and service planning. I have indicated 
that we had to obtain research funding to establish the molecular genetics laboratory. 
 
The absolute diagnosis of CF is based on the determination that the individuals carry 
mutations in the CFTR gene and on each allele. Our feeling was that the severity of 
the clinical disease was similar to that associated with the mutation ∆F508. However, 
it was with some surprise that the rarely found mutation S549R (T→G) was 
associated with CF in the majority of our patients. Indeed, all the patients initially 
seen were homozygotes for this mutation. Our next important finding was that a few 
children were, in fact, homozygotes for the ∆F508 mutation. However, these children 
belonged to the minority group of UAE citizens who belong to the Baluch ethnic 
group. From the study of patients to date, it appeared that 96% of CF children had one 
of these two mutations. An attempt was made to compare the clinical severity of an 
age and sex matched group of children who were homozygous for the two mutations. 
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The small number of children available to age and sex match frustrated these attempts 
to confirm or refute my feeling that the S549R mutation had an even more severe 
clinical outcome than that of the ∆F508. Enough information was available to add 
further evidence; however, that S549R is associated with severe disease and it 
probably at least equates with that of the ∆F508 mutation phenotype. 
 
The next area that was addressed was the question of how common CF was in the 
UAE. To determine the frequency of carriage of the two mutations identified, a 
random sample of the population was required. This has been achieved as well as 
possible in the Emirati society. The combined estimated frequency for individuals 
homozygous for a mutant CF allele is 1 in 64 of the national population Taken that the 
Emirati national population was 750,000 and we were aware of at least 50 children 
with CF, an extremely crude prevalence rate of 1in 15,000 could be assumed. Using 
our CF mutation frequency of 1 in 64, then a frequency of 1 in 15,000 could be 
obtained. This calculation is not applicable in a population in which over 50% of the 
marriages are consanguineous. Further, there has probably been a major "loss" of CF 
patients by attrition. The birth incidence figure, thus calculated, using a formula 
allowing for consanguinity is one of 1 in 4318 births for all nationals. 
 
No information has been published about CF in Oman. I had identified one child who 
was an Omani national. The extension of our studies to Oman confirmed the presence 
of CF in that country. Again we were surprised that the major mutation associated 
with CF was S549R in a homozygous state. As in the UAE, those of Baluch descent 
were homozygous for the ∆F508 CFTR mutation. Data collected from thirty 
diagnosed patients pointed to the disease being of a severe nature there also.  
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 The accumulated knowledge of CF in the Eastern Arabian Peninsula allowed some 
speculation as to the likely original sources of the mutations. It is suggested that that 
the founding mutation of the S549R mutation arose in what is the present day 
Republic of Yemen. The ∆F508 may have arisen in the ancestral people of the 
geographical area Baluchistan, spanning Pakistan, Iran and parts of Afghanistan. 
 
Overall, CF produces a significant health problem for children in the Eastern Arabian 
Peninsula. The gene mutational findings are different for the major ethnic groups. 
Evidence points to the fact that children have and are dying from the disease due to its 
non-recognition or suspicion. Increased awareness of the condition is required and 
aggressive treatment regimens are essential. The combination of climate, geography 
and genetic factors has made CF in the UAE and Oman a lethal disease. This situation 
can be changed by increased education about the condition for doctors and the public 
at large. Therapeutic regimens must include allowances for the climatic extremes in 
the region. 
 
 
Concluding Summary 
The contribution made to new knowledge about CF in Eastern Arabia as described in 
this thesis and the input into disease management to can be summarised as follows: 
1. Recognition of the disease as being present throughout both countries and it not 
being as rare as previously thought. 
2. Raising the level of awareness of the condition in the UAE of Paediatricians and 
in the public in general by publications, presentations and seminars. 
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3. Obtaining funding to develop a laboratory to define the CF mutations present in 
the population. 
4. Outlining the molecular genetics of CF in the UAE and Oman. Establishing that 
the S549R mutation is found almost always in a homozygous state in Bedouin 
UAE and Omani nationals. 
5. Recognising that the mutation ∆F508 is frequently found in those of Baluch 
descent and usually in a homozygous state. 
6. Providing the first reports of CF in the UAE Bedouin population and the first 
reports of its mutational basis. 
7. Providing the first reports of CF in Omani nationals and the associated CF 
mutations. 
8. Defining CF in these populations as having a severe clinical presentation and 
equating the phenotype to the genotypes. 
9. Presenting the largest series of patients with the S549R mutation ever reported. 
10. Providing an estimate of birth frequency for CF in the UAE. 
11. Contributing to the new knowledge that a mutation in the promoter region of the 
CFTR can modify the clinical phenotype of the S549R mutation. 
12. Presentation of hypotheses regarding the two gene mutations and their ethno-
geography. 
13. Establishing a service for CF children in the UAE. 
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Figure Edward from Palestine 
 
 218
